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1 Introduction 
1.1 Drug Delivery 
Drug Delivery, i.e. bringing a drug to its site of action, is a core discipline of pharmaceutical technology. 
The drug has to be delivered from the outside of the body to the blood stream and from there to its 
target site. 
In principle, two different types of application exist: Local application in which the drug is directly 
applied to the site of action, like zinc paste to an area of sore skin, and systemic application in which 
the drug is distributed throughout the whole body, as for example in case of painkillers. The main 
difference between both ways of application is that in the latter way the drug passes the blood stream 
as systemic compartment before reaching its target. There are other compartments, like the lymphatic 
system, [1, 2] that are also aspects of systemic drug delivery, but for matters of simplicity these are not 
considered in this context. 
If possible, local delivery is favored, as only the site of action is exposed to the drug and thus side 
effects are diminished; however, in many cases the site of action is not easily accessible so that 
systemic delivery is the only option. In most cases, systemic delivery is realized by oral delivery of 
tablets and capsules, being the most convenient way. The parenteral route of application, though of 
invasive character, also shows its advantage as the drug is directly applied to the blood stream with no 
biological barrier that has to be crossed. In rare cases, rectal (e.g. paracetamol suppositories) and 
pulmonary (e.g. inhalable insulin and dihydroergotamine mesylate[3]) applications are also possible. 
These cases usually have the problem that patient compliance is rather bad. For rectal application, 
many people feel uneasy with the application itself. In case of the pulmonary medicines, the inhalation 
process is demanding, such that patients fail to deliver the drug into their lungs. Often, most of it is 
deposited in the throat or the upper bronchus instead of the alveolus. However, both have an 
important advantage over oral application as there is no first pass effect and thus drug concentrations 
applied can be lower. For the lungs: despite having several clearance mechanisms such as alveolar 
macrophages and efflux drug resistance proteins, there is no restrain to a quick uptake of drugs into 
the blood.[4] For systemic drug delivery, the oral route of application is usually the option of choice. In 
contrast to the parenteral application, formulating and storing the medicinal product is rather easy 
and economical. Furthermore, it can easily be applied by the patient himself and thus shows a good 
compliance. Therefore, only drugs that cannot be administered orally are usually available as 
parenteral medicines. Whether a drug can be administered orally or not, depends on its physical and 
chemical properties: mainly on solubility in water and permeability through cell membranes. Therefore, 
it is common to classify drugs by these two characteristics, according to the BCS (Biopharmaceutical 
Classification System)). The (four) classes of the BCS roughly indicate how hard or easy it is to deliver 
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drugs orally. While for BCS class I drugs it is sufficient to bring the drug just to the intestine (high 
solubility and high permeability), it is different for the classes II (high permeability, low solubility), III 
(low permeability, high solubility), or even class IV where both parameters are low.  
The problem with drug delivery systems for parenteral application is that they have to be produced 
and kept sterile and that they have to be applied by trained personnel, which makes them very 
expensive. Furthermore, parenteral applications are mostly injections and infusions. Since a dislike of 
needles is quite common among the population, parenteral application is minimized to absolutely 
necessary applications. 
In recent years, biological drugs (biologicals), like DNA-, RNA-, peptide-, or protein-based drugs, started 
to play a major role in therapy. Thanks to recent progress in biotechnology, many different biologicals 
are now available in therapeutic quantities.[5-7] The disadvantage of biologicals is that they are, in 
contrast to simple chemical compounds, comparatively large and susceptible to degradation. The size 
of the molecule greatly reduces the permeation through cell membranes.[8] Furthermore, these 
biological molecules are by default objects of operation to biological lifeforms, therefore the body has 
countermeasures to defend itself against those molecules coming from the outside. Especially 
deoxyribonucleases and ribonucleases are widely spread in the body and disintegrate DNA[9] and 
RNA[10] rapidly. Proteases exist in the gastric intestinal tract, not only with the function of 
countermeasure but mainly as enzymes for digestion of food proteins. It is an unfortunate but 
evolutionary expectable coincidence that the easiest route of administration is blocked for this kind of 
drugs. In order to provide them as drugs, an advanced technological approach is necessary. 
 
The position of micro- and nanoparticles in pharmaceutical technology 
The conservative dosage forms of pharmaceutical technology, like tablets, capsules, creams and 
powders, have been sufficient to provide patients with functional medicines for a long time; however, 
the newer biological therapeutic agents are not only more powerful, but they also are more demanding 
in terms of storage and delivery; therefore, new dosage forms had to be identified. Microparticles and 
subsequently nanoparticles including liposomes were the answer to that problem.[11] This seems 
reasonable, as very small structures can be equipped with all necessary properties for being delivered 
right to the spot.[12-14] Core requirements of this delivery system is the protection of the active 
pharmaceutical ingredient (API), delivery over biological barriers to the site of action and proper 
release (kinetics) from the particle. To meet all these requirements is not an easy task, and thus for 
every API an own dosage form has to be constructed, specifically tailored to its needs. 
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1.2 Polymeric particle preparation  
There are numerous ways of preparing polymeric particles for pharmaceutical application. In general, 
all polymeric particles can be divided into two different groups: particles made of hydrophilic polymers 
and particles made of hydrophobic polymers. For most applications, hydrophobic particles are used as 
their preparation is rather simple, but many new drugs (including biologicals) are hydrophilic and the 
encapsulation of the compounds into hydrophobic polymers is difficult, such that hydrophilic particles 
are favored for this kind of application. 
 
1.2.1 Preparation of hydrophobic PLGA particles 
One of the mostly used substances for preparing hydrophobic particles is PLGA (Polylactic-co-glycolic 
acid). It is a co-polymer made of lactic acid and glycolic acid monomers and thus similar to poly lactic 
acid and poly glycolic acid. As lactic acid is more hydrophobic than glycolic acid, it is assumed that the 
hydrophobicity of the PLGA polymer can be adjusted by the ratio of the two monomers along with its 
swelling and degradation behaviors.[15, 16] It is biocompatible and biodegradable, as it is turned into 
lactic acid and glycolic acid monomers by hydrolysis.[17, 18] Lactic acid is further degraded to water and 
carbon dioxide [19] and glycolic acid is mainly metabolized to oxalate in the liver, as experiments by 
Brady and Farinelli in rats indicated.[20] Furthermore, there exist [21] FDA and EMA approved implants 
made of PLGA, and therefore PLGA is a suitable candidate for particle preparation. 
The two most common ways of preparing PLGA nanoparticles (and microparticles) are the emulsion 
method [22-29] or the precipitation method.[30-33] For the latter one, PLGA is dissolved in an organic 
solvent that is miscible with water such as acetone. The solution is then dropped or injected into stirred 
water. The acetone directly mixes with water, so that PLGA, unable to mix with water, precipitates as 
nanoparticles. For matters of drug encapsulation, the drug can be dissolved in the organic solvent 
together with the PLGA and should then, during particle formation, be encapsulated. These methods 
work especially well for rather hydrophobic drugs. Hydrophilic drugs are more difficult to encapsulate 
as they have more attraction to the aqueous phase.[32] For the emulsion method, PLGA is dissolved in 
an organic solvent that is partially miscible with water. An emulsion is formed with the organic solvent, 
with PLGA being in the inner phase. By increasing the water volume beyond the miscibility border of 
the two partially miscible solvents, the organic solvent mixes with water and PLGA precipitates as it 
cannot mix with water. Thus, nanoparticles are formed. In case of hydrophilic drugs, often double 
emulsion methods are used. Double emulsion techniques work well for microparticles, as 
nanodroplets can be incorporated into the microparticles.[34] This method is used as well for 
nanodroplets in nanoparticles;[35-37] however, it has not yet been demonstrated, that there are smaller 
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nanodroplets in nanoparticles. Other options include surface coatings of the nanoparticles or the use 
of stabilizers that increase the amount of drug inside the nanoparticles.[22, 38] 
Surface modifications of PLGA nanoparticles for the purpose of functionalization are a common topic 
in pharmaceutical research. Usually three different purposes of surface modification exist: targeting, 
release modification and bioavailability (see also section 1.3.3). In case of surface modification, for 
example antibody coatings can be used to target nanoparticles to cancer cells.[39] In case of modifying 
release kinetics, often polymers are used to surface-coat particles layer-by-layer wise.[40-42] For 
enhancing bioavailability, for example penetration enhancers [43] can be used as coating material,[44] as 
it will be shown for PLGA in this thesis.  
PLGA nanoparticles can be characterized in many ways. The most common characterization methods 
are size measurement by Dynamic Light Scattering (DLS) methods, but in some cases Nanoparticle 
Tracking Analysis (NTA) is used as well. The NTA usually has a better resolution, especially in case of 
multimodal distributions, but its preparation is less simple.[45] Zeta potential of particles is usually 
measured by Laser-Doppler Velocimetry (LDV). While zeta potentials are usually negative because of 
the carboxylic end group of commonly used PLGA types, the size of particles usually differs. Common 
sizes of PLGA nanoparticles are going down to 100 nm. The sizes usually depend on different 
parameters, such as the stabilizers used, the concentration of PLGA in the organic solvent during the 
preparation and the size of the emulsion that is prepared in case of a preparation by emulsion-based 
methods. 
 
1.2.2 Preparation of hydrophilic dextran particles 
Hydrophilic particles 
Preparing hydrophilic particles is usually a much greater challenge than preparing hydrophobic 
particles, due to the hydrophilic nature of our environment. Prepared particles have to be kept and 
stored dry during the whole process of preparation and afterwards. Even air humidity can be a 
problematic factor as some substances are hygroscopic. The smaller the particles are, the higher is the 
surface to mass ration and thus hygroscopic effects are stronger.  
For that reason, hydrophilic particles are often prepared as gels. The forces of the gel structure keep 
the particles in shape, despite the influence of surrounding water. Both, covalent [46] and non-covalent 
gels, are utilized for stabilization. Among the covalently bound gels, gelatin is a prominent example.[47] 
Due to its protein nature, gelatin particles can be crosslinked with for example glutaraldehyde to form 
stable particles. That also illustrates a drawback of covalent gels: peptide and protein drugs tend to be 
crosslinked with the polymer mesh rendering them non-functional. Non-covalent gels have less 
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problems with that issue. But as they are usually held together by ionic forces, they are also less stable, 
because the ionic bonds in water are weaker by one power of 10, compared to covalent bonds.[48] 
Another way to reduce the affection by water is the use of larger molecular weight polymers; however, 
that is not always possible as the molecular weight usually changes the viscosity, and thus the whole 
process of particle preparation can be affected. 
 
Dextran and Dextran particles 
Dextran is a polymer based on glucose monomers, which are connected via α-1,6 and α-1,4 
connections. The dissolution of the polymer in water depends very much on its average molecular 
weight, but even polymers of around 40 kDa can easily be dissolved to an extent of a > 50% (m/v) 
solution in water.[49] Due to that strong hydrophilicity, lower molecular weight dextrans tend to be 
strongly hygroscopic. Dextran is non-toxic, biocompatible and biodegradable, and is FDA approved for 
parenteral use, for example as blood plasma expander.[50-53] 
Dextrans have no groups or structures that work well for forming non-covalent gels in contrast to, for 
example, alginates. Many preparations of dextran particles in literature therefore use chemically 
modified dextran variants.[54-56] One exception to that is the gelation of dextran with potassium ions. 
Six hydroxyl groups of dextran can form a pocket that is usually occupied by a water molecule; however, 
in the presence of potassium ions the ion moves into the pocket and binds the slightly negative charge 
of the dipols of the hydroxyl groups to its positive charge. The effect only works with potassium, as 
sodium ions are too small in size, whereas e.g. rubidium ions are too large. The gels that are produced 
in that way are rather strong and inflexible, but large amounts of potassium (around 3 mol/L) are 
necessary, rendering them unusable for parenteral applications, as potassium ions are toxic in that 
concentration.[57, 58] 
Examples for dextran particles exist in great number: Particles for delivery of substances like 
doxorubicin and cobalamin have been shown.[59, 60] Combined approaches of magnetic iron oxide and 
dextran nanoparticles also exist; however, here dextran is usually more used as a coating for the iron 
oxide nanoparticles.[61-63] In some cases, dextran microparticles are formed as gel particles, therefore 
modified dextrans are used. If they are smaller in size, they are often called “nanogels” in literature.[64-
67]  
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1.3 Biologicals – Structure and setting 
1.3.1 Biomolecules 
The delivery of biologicals can be much more complicated, compared to the delivery of small molecule 
drugs. Biologicals are in most cases polymeric or at least oligomeric structures. In case of DNA and RNA 
they are chains of nucleosides connected with each other at their 3’ or 5’ end of their ribose sugar by 
a phosphate group. DNA and RNA are chemically very stable against heat and pH change – double 
strands may disconnect but will reconnect again quickly, once the conditions return to normal state, 
as for example in case of polymerase chain reaction. However, the human body has a lot of enzymes 
that cut and degrade DNA and especially RNA, serving as countermeasures against infectious 
organisms.[10, 68, 69] Asides from DNA and RNA, peptides and proteins are functional biomolecules used 
for therapeutic purposes. Proteins/peptides are chains of amino acids, which are joined by their amino 
and carboxyl group. Each amino acid has one out of 21 (in case of the human body) side chains at their 
central carbon atom. These chains fold in certain ways and thus form an active protein. Proteins can 
have many different functions, like catalysis (in case of enzymes), transport, signaling, structure 
building, storage and many more.[70] The formation of a protein depends on its primary structure (i.e. 
the sequence of different amino acids), as the molecule folds into its energetically most favorable 
position. As proteins can be very long, – more than 2000 residues are possible – the correct folding 
does not always occur by its own and there are biological mechanisms to help those proteins to fold 
properly. Proteins thus fold into secondary structures and super secondary structures which are a small 
set of structures of the primary chain. Secondary structures usually form between non-
interchangeable groups of amino acids, such that the residue groups only have a limited, mostly 
sterical influence on the structure. In contrast to that, the tertiary structure is mainly shaped by the 
properties of the residue groups of the amino acids, like their sterical behavior but also their 
electrostatic properties and hydrophobic domains. More than that, such folded proteins can attach to 
each other forming a quaternary structure. The way these structures form, especially the tertiary 
structure, indicate that they are very sensitive to changes in temperature and pH as these factors may 
change the energetic balance which is responsible for their structure. A once deformed protein may 
not be able to fold itself back into its original confirmation, and thus loses its ability to pursue its task. 
While the beforehand mentioned DNA and RNA are very stable in this case, proteins are not. On the 
other hand, while degrading enzymes for DNA and RNA are found in many fluids and on the skin of the 
human body [9, 68, 71], proteases can mainly be found in the stomach and the intestine. Except for the 
case of oral application, these do not play a significant role for drug delivery. Peptides are like very 
short proteins. They have rarely secondary structures and their tertiary structures are usually limited 
to disulfide bonds, if any. While peptides are still sensitive molecules that can be degraded easily, they 
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are more stable to changes in temperature and pH than proteins, and in the human body there are not 
as many enzymes degrading them as for DNA and RNA. 
 
1.3.2 Pharmaceutical use of biologicals 
Conventional medicines rely on small molecule drugs that alter the body’s chemistry. This usually 
happens, when for example the molecule docks to a receptor or concentrations of the molecule cause 
changes in the metabolic pathways. This way of treatment is often actually an intoxication, which has 
a positive side effect on recovery of the patient, and in best case it does not have other negative side 
effects. Some biologicals, on the other hand, can work in a different way. Many of the used peptides 
are hormones or signaling entities that do not intoxicate the body but replace the body’s own 
substances that are missing due to a disease (e.g. insulin). If RNA is used as a biological medicine, they 
often have similar purposes as the peptides. Proteins again work on higher order: As proteins are the 
actors of the metabolism, by introducing them into an organism it is possible to directly execute certain 
reactions. This can be beneficial for genetic diseases, where certain proteins are missing or 
underexpressed. DNA again works on a higher order than proteins do, as the DNA/gene delivery is able 
to transfect the cells, and thus gives them the ability to produce a protein missing e.g. due to a disease. 
While the possibilities of biologicals are very promising, it is also very difficult to deliver them to the 
right compartment within the body and preserve their functionality. Proteins and RNA are generally 
the most difficult biologicals, as they degrade very quickly. The delivery of biologicals is subject to a lot 
of current research.[72, 73] 
 
1.3.3 Drug delivery of biologicals  
Biologicals commonly serve as the therapeutic agent in a formulation; however, they can also have 
other tasks. Sometimes they are used as targeting molecules.[74] In this case, a modified drug delivery 
system can be targeted to certain places by binding a biological on its surface.[75, 76] Also the release 
pattern of a drug from particles can be changed by the usage of enzymes that degrade the particle.[77, 
78] A third alternative is to use biologicals on the surface of particles to mediate an uptake through a 
biological barrier.[79] In this thesis the human lactoferrin peptide – a known penetration enhancer – is 
used as a particle modification. 
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1.3.4 Desmopressin and its medical application 
Desmopressin, which is used in the thesis as therapeutic agent, is a synthetic analogue for the peptide 
hormone vasopressin. It has nine amino acids of which one is D-arginine. The amino group on the N-
terminal side is cut off and an amino group has been attached to C-terminal side of the peptide. There 
are two cysteine residues that connect with a sulfur bond and form its secondary (ring) structure. 
Desmopressin is an antidiuretic drug being used to treat diabetes insipidus.[80] It can also be applied to 
prevent nocturnal enuresis in adults and children, and has thus a broad application on the market.[81, 
82] Furthermore, it has anti-coagulopathy effects that are subject of research since the late seventies.[83-
85] It has been tested for uses to counter effects of acetylsalicylic acid,[86] blood loss after cardiac surgery 
[87, 88] or bleeding disorders.[89] 
 
1.4 The lung  
1.4.1 Anatomic key features and barrier properties of the lung 
The lung is responsible for the gas exchange (carbon dioxide and oxygen) of the blood. It is divided into 
a right lung, consisting of three lobes, and a left lung, consisting of two lobes. Connected to the nasal 
region is the trachea which first breaks down to the bronchus, then the bronchioli and later the alveoli. 
While bronchus and bronchioli are primarily responsible for conducting the airstream, the lower part 
of the bronchioli and the alveoli are responsible for the gas exchange.[90] The transport of oxygen and 
carbon dioxide is mediated by hemoglobin and myoglobin. In both cases, the gas is bound to an iron 
atom of the heme complex. The exchange happens by diffusion, mainly driven by partial gas pressures 
of the environment and of blood. To allow an optimal exchange, the alveoli have a squamous 
epithelium with a thickness of around 100 – 200 nm,[91] a total inner surface of around 140 m2, [92] and 
they are well-perfused because of capillary blood vessels. The conducting airways in contrast, have a 
much thicker tissue, and an inner surface of just 2 m2. As larger components do not bypass the cell 
membrane easily, a large surface with a thin epithelium and a good perfusion is an ideal place to start 
for drug delivery.[91, 93] The alveoli are coated with the alveolar lining fluid which decreases the surface 
tension. It avoids the adherence of the tissues among each other and thus prevents the collapse of the 
lung.[94] The gas exchange is also supported by the fluid, and it probably passively supports the immune 
system by preventing adherence of bacteria. The free fatty acids in the fluid help to inhibit microbial 
growth.[94]  
As the speed of the air stream changes through the different branches of the lung, particles are 
separated by their sizes. In general, the larger the particles are, the earlier they impact into the tissue 
of the bronchus (with exception of porous particles, as density also plays a role [95]). Particles of the 
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size of 10 µm and larger are stopped by the bronchus by 100%, while for particles of 5 µm only around 
80% impact in the upper airways.[96] This gradually goes down to 0% for 1-2 µm particles.[96] In the 
deeper lungs the speed of the air stream is slower and deposition is then mainly driven by gravitational 
forces on the particles. Particles smaller than 1-2 µm reach the deep lungs, but they are too small to 
be affected by gravity, so they are rather exhaled than deposited.[96] If particles become smaller than 
200 nm, diffusion effects again mediate a deposition in the deeper lungs.[96] 
 
1.4.2 Pulmonary clearance mechanisms 
Mucociliary Escalator 
Around 30-65% of the cells in the airways are populated with small cilia [93] which agitate in a 
concentrated metachronal pattern to move the mucus up the throat where it is swallowed. This 
mucociliary escalator is the primary cleaning mechanism in the bronchus/bronchioles. It removes 
unwanted substances, primarily larger particles stuck due to impaction, from the conducting airways 
(see section 1.4.1). In the lower regions of the conducting airways, less cells with cilia can be found 
than in the upper regions. The speed of mucus movement can be measured with a method developed 
by Yeats et al. They obtained a geometric mean value of 3.6 mm/min from a study with 40 subjects.[97] 
 
Alveolar Macrophages 
For removing dust particles and bacteria from the deeper lung, pulmonary macrophages take up 
foreign objects by phagocytosis.[98, 99] Such internalized substances are then degraded in the 
phagosome. During the uptake process, macrophages secrete chemokines that attract neutrophil 
granulocytes to enhance that body’s capability to remove bacteria or dust. Furthermore, the 
phagocytosis produces some reactive species (e.g. oxygen derivatives) that are toxic for the 
surrounding bacteria. Asides from phagocytosis, macrophages also serve as coordinators for the 
immune system by flagging spots with cytokines like TNF-α or several interleukins.[100, 101]  
Macrophages in the lung can occur in three places: [102] Directly in the alveoli, in the conducting airways, 
where they are being transported by the mucociliary escalator, or they can sit beneath the mucus and 
as interstitial macrophages in the tissues of the lung. The last kind can sit in many places such as 
connective tissues, lymph nodes and alveolar walls. Macrophages that are being removed from the 
lung either move up the throat via the mucociliary escalator and are swallowed and digested or they 
are transported from the lung via the lymphatic system. 
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1.5 Pulmonary Drug Delivery  
Delivery of drugs along the pulmonary route is a very old subject. Smoking tobacco, for example, or 
other herbs, has been common in many cultures for a long time. Also the usage of pulmonary delivered 
anesthetics has a long tradition,[103] especially since the discovery of chloroform.  
 
1.5.1 Systemic Drug Delivery into the lungs 
As mentioned in section 1.1, for systemic application the drug has to be delivered to the blood. To 
achieve this in the lungs, the drug has to pass the squamous epithelium in the alveoli. The advantage 
of systemic drug delivery is that the epithelium is only 100-200 nm thick and the blood vessels lie 
directly behind the epithelium ready to take up compounds – usually oxygen – from the environment; 
however, the cells of the epithelium in the alveolus are also connected by tight junctions that block 
compounds from passing between the cells, and alveolar macrophages remove most of the 
compounds – depending on their size – remaining on the cells for too long (see section 1.4.2). Drugs 
can reach the blood vessels either by passing between two cells (paracellular transport) or by entering 
the cell on one side and leaving the cell on the other side (transcellular transport). Despite the large 
surface of the alveolus, the thin barrier and the close blood vessels, the barrier should not be 
underestimated. The transport of not well-permeable molecules into the blood stream remains a 
challenge. To improve the uptake of drugs, absorption enhancers such as oleic acid or others can be 
added.[104] There are also peptidic penetration enhancers like the hLF-peptide that mediate the 
diffusion into the cell for transcellular transport.[105] Paracellular transport is more desirable for 
systemic delivery than transcellular transport, as the drug is directly moved to the blood vessels; 
however considering the strong clearance mechanisms of the lung, a quick transport into the cells and 
slower further transport to the blood vessels might be advantageous, compared to a slow paracellular 
transport. 
 
1.5.2 Short historical overview of pulmonary application 
Pulmonary application has been in use for as long as mankind’s records go back, mostly for application 
of alkaloids. Around 4000 years ago, in India smoking Datura preparations and other herbs is 
conveyed.[106] In ancient Egypt (around 1500 BC) black henbane vapors were inhaled, and probably the 
first inhaler devices known were made by the Greek (around 400 BC).[107] In the middle ages, inhalation 
therapy can also be cited, as it appears in the “Treatise on Asthma” by Moses Maimonides.[107] 
However, it is only a small part of the treatment approach on asthma and also contains suggestions 
like to breathe clean air and live outside the city. This also might be due to the definition of asthma 
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back then, which does not meet with today’s definition.[108] Also the smoking of tobacco (and other 
herbs) by Native Americans, yet not for medical purposes, is an example for inhalation of biologically 
active substances. Later, in the late 18th and early 19th century, inhalation again was reported in Britain 
and the United States.[106] Asthma cigarettes, which were made of atropine containing herbs, became 
a common medicine at the time.[109] The first device called inhalator was a tin vessel made by the British 
physician John Mudge.[110] The first pressure driven inhaler and the first dry powder inhaler were then 
invented roughly 70 years later in the middle of the 19th century.[110] Another hundred years later, in 
the middle of the 20th century, the asthma cigarettes came under criticism because in some cases they 
caused poisoning.[111] More advanced metered dose inhalers came up and could take the place of the 
cigarettes easily, as also adrenalin as therapeutic agent for asthma had been found. Successively, new 
and more advanced inhalators came on the market. In the 60s, ultrasound nebulizing devices were 
invented, the first modern dry powder inhalers came up in the 70s,[110] leading to the devices used in 
today’s medicine. One of the first biologicals and probably the most well-known peptide drug is insulin. 
To treat diabetes mellitus, the patients have to inject insulin into their adipose tissue to mediate the 
uptake of sugar from blood into cells. However, the compliance of injections is rather low and plain 
oral administration is impossible, since peptides are a natural food source to human beings. The 
pulmonary route, having no digestion enzymes like the stomach and no first pass effect, seemed a 
promising target. First reports about applying insulin via the pulmonary route can be found back in 
1925.[112] Even though the drug was functional, the efficiency was rather low. Around 50 years later 
some research groups picked up the idea again and tried to administer aerosolized insulin to patients, 
which was greatly summarized by Patton et al. in 1992.[91] However, there were problems to overcome. 
The majority of the aerosol did not reach the alveolar compartment, such that patients had to be 
trained to breathe the aerosol into their lungs to maximize the effect. Rapid absorption in the lungs 
resulted in too high peak concentrations and short effects, as well as irritations in the respiratory 
area.[113] 
The problem of irritation can generally be solved by encapsulating the drug in a compatible host. 
Furthermore, in the second half of the 80s some studies in animals [114, 115] showed that the use of 
liposomes could result in a sustained effect which would solve the problem of rapid absorption. In 
1992 Liu et al. encapsulated insulin into liposomes to investigate the effect.[116] However, the effect 
did not result from the release pattern of the liposomes, as pure insulin co-administered with empty 
liposomes yielded the same results. But nevertheless, a sustained effect and a stronger hypoglycemic 
effect was observed. Liposomes could also be used for targeting to specific cells in the respiratory area 
which has been summarized by Schreier et al. in a review on pulmonary delivery of liposomes.[113] To 
solve the problem of deposition, improved inhalation devices were created which made inhalation 
easier for patients.  
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Besides that, in 1997 Edwards et al. created “large porous” particles for pulmonary administration that 
were big enough to carry an acceptable amount of insulin with a very low density, such that the 
particles did not suffer from impaction in the upper airways.[95] Thus upon inhaling, a larger amount of 
particles reached the alveolar compartment. Large porous particles can either be prepared from a 
polymer that holds a drug or from the drug itself, as it was done by Vanbever et al. with insulin.[117] 
Further studies resulted in the first commercially available, FDA approved, inhalable insulin medicinal 
product called Exubera® (marketed by Pfizer Inc.).[118] However, it was only available for a short time 
(2006-2007) as the demand was very low. The main reason was that it was significantly more expensive 
than injected insulin and meant no improvement for the treatment of the disease.[119] Also effects on 
patients due to heavy smoking and asthma were not considered in the clinical trials.[119] 
Searching for “inhaled insulin” publications in the PubMed database yields over 1000 results. Most 
publications have been made in the period since 2001, peaking 2006 (99 publications) and 2007 (123 
publications). After 2007 the amount of publications decreased to around 30 per year. However, the 
topic is still subject to research and another formulation of inhalable insulin named Afrezza® by 
MannKind Corp. has recently been approved,[120] continuing the story. The marketing of Afrezza®, 
however, was done by Sanofi with only little success. The product financially never met its expectations, 
resulting in Sanofi dissolving its contract with MannKind in early 2016.[121] This leaves MannKind 
searching for a new distributor.[122] 
 
1.5.3 Differences between Dry Powder Inhalers and Metered Dose Inhalers 
Pulmonary administration has a lot of advantages and only few, but large disadvantages. The biggest 
disadvantage is the application itself, because patients need to be trained to inhale the formulation in 
a correct way. If the inhalation is not executed properly, the main amount of the drug can be stuck in 
the mouth, the throat or the bronchial region of the lung instead of reaching the alveolus. Newer 
developments of inhaling devices support the patients in this matter, and particulate formulations can 
further help to avoid a deposition in the wrong place.[95] 
Most modern inhalers have, for example, a dose counter that allow patients to control how many 
doses have been taken or are yet available in the device. They have overdose protections and properly 
shield their loaded drugs from the environment.[123] There are two main classes to be distinguished: 
dry powder inhalers and metered dose inhalers that usually provide liquid aerosols. The metered dose 
inhalers were developed in the middle of the 20th century (see section 1.5.2). Originally, they used 
chlorofluorocarbons as propellant; however, in the 90s they were refitted to work with 
hydrofluoroalkanes for ecological reasons. An advantage of the dry power inhaler is that it will only 
discharge if the negative pressure is high enough, and thus the drug can directly go to the lung. In 
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contrast to that, in case of the metered dose inhalers, breathing in and discharging the inhaler has to 
be coordinated. On the other hand, dry powders can induce coughing and therefore they are not 
always the right choice. 
 
1.6 Motivation and Goal 
The goal of this thesis is to create a most versatile drug delivery system. The predominant route is 
pulmonary application, while the routes for oral, dermal and parenteral application should not be 
excluded a priori. For a pulmonary delivery system, its key problems, i.e. the physical structure of the 
lungs (see section 1.4.1 and 1.4.2) and the problems patients have with application (see section 1.1 
and 1.5.3), have to be addressed. Fortunately, there are commercially available devices (see section 
1.5.3) that help patients applying aerosol, such that this aspect does not have to be part of this thesis. 
The physical structure of the lung as a problem for pulmonary delivery can be discriminated into two 
problems. One being the problem of deposition in the correct area in the lungs (see section 1.4.1) and 
the other being the problem of absorption of API into blood stream, which often requires penetration 
enhancers (see sections 1.2.1, 1.3.3 and 1.5.1). The latter only occurs for systemic delivery at which 
this thesis aims. Besides these physiological problems, also the API has requirements for its transport. 
Biological APIs, such as Proteins, Peptides, DNA and RNA, are sensitive to degradation (see section 
1.3.1 and 1.3.2). Since chemical properties like hydrophobicity of theses APIs have to be taken into 
account as well, many different methods of encapsulating exist (see section 1.2.1 and 1.2.2). If the 
system is supposed to be truly versatile, then it needs a certain flexibility to be adjustable to the API 
used. The main factor for that matter is the polymer that is used for the encapsulation. An 
encapsulation will only work well if the polymer and the API can be brought together. Therefore, a 
system where the polymer can be exchanged without changing the method of preparation, is desirable.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Polymers 
The Polylactic-co-glycolic acid (PLGA) was obtained as Resomer RG 503H (50:50 ratio) from Evonik 
Industries (Darmstadt, Germany). Fluorescently labelled PLGA was prepared on site: briefly, 
fluorescein amine was coupled to 50:50 PLGA (Resomer RG 503H) by a 4-(Dimethylamino)-pyridin 
(DMAP) catalyzed reaction in acetonitrile, as described by.[124] Chitosan used is Novamatrix Protosan 
UP CL 113 obtained from FMC BioPolymer AS (Sandvika, Norway). Glucomannan (food quality) was 
bought from Now Foods (Bloomingdale, IL, USA). Alginate was purchased from Carl Roth GmbH + Co. 
KG (Karlsruhe, Germany). Lignin (alkali), dextran (150 kDa from Leuconostoc mesenteroides), and 
gelatin (from bovine skin) were obtained from Sigma Aldrich (Steinheim, Germany). 20 kDa dextran 
was ordered from Tdb Consultancy (Uppsala, Sweden). 
 
2.1.2 Stabilizers 
Polyvinyl alcohol (PVA) was obtained as Mowiol 4-88 from Kuraray Europe GmbH (Hattersheim am 
Main, Germany). Tween 21, Tween 85, Span 80, Span 85, Polyethylene glycol (PEG) 400, Pluronic F-
68/Poloxamer 188 and Pluronic F-127/Poloxamer 407 were purchased from Sigma Aldrich (Steinheim, 
Germany), Brij O2 was bought from Croda GmbH (Nettetal Kaldenkirchen, Germany). 
 
2.1.3 Peptides  
Desmopressin acetate was a gift from Evonik Industries (Darmstadt, Germany), bought from Ferring 
Arzneimittel GmbH (Kiel, Germany). The human lactoferrin peptide (hLF-peptide) was obtained from 
EMC (Tübingen, Germany). 
 
2.1.4 Solvents 
Organic solvents for precipitations and washing were obtained from Sigma Aldrich (Steinheim, 
Germany) in HPLC-grade qualities. (CHROMASOLV® Plus, for HPLC ≥99.9%), acetonitrile 
(CHROMASOLV® Plus, for HPLC ≥99.9%) and acetone (for HPLC ≥99.9%). Ethanol was obtained as 
Ethanol absolute ≥99.8% from Sigma Aldrich (Steinheim, Germany) as well. Pentane was obtained in 
reagent grade (98% purity) and hexane in quality for HPLC ≥95%, both from Sigma Aldrich (Steinheim, 
Germany) as well. Liquid paraffin was obtained from Merck KGaA (Darmstadt Germany) in quality Ph. 
Eur., BP, NF, JP. 
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2.2 Methods 
2.2.1 Theoretical backgrounds of methods used 
Particle Size Measurement by Dynamic Light Scattering (DLS) 
Dynamic Light Scattering (DLS), also called Photon Correlation Spectroscopy (PCS), is one of the most 
common techniques to determine the size of nanoparticles. There are different companies offering 
devices like HORIBA Ltd. and Wyatt Ltd.; however, most laboratories, like in our case as well, use a 
Zetasizer device by the company Malvern Instruments Ltd. (Worcestershire, United Kingdom).  
For measuring the size of particles, a laser beam is pointed at a nanoparticle suspension in a cuvette. 
The light is scattered by the nanoparticles and partly reflected towards a detector. Since the scattering 
also results in a phase shift for some of the light waves emitted from the laser, it happens that some 
light waves annihilate each other by destructive interference, while others brighten up due to 
constructive interference. The amount of constructive and destructive interferences in a moment of 
measurement results in a brightness-signal on the detector. The quicker the nanoparticles move in 
their suspension, the quicker the brightness-signal on the detector changes. The device calculates an 
autocorrelation function with these brightness values. That means, it compares the value at a certain 
time point with a series of values before that time point, and on this basis it calculates the size of the 
particles (Equation 2.1). This method works, because if no energy is applied to move the nanoparticles 
within the suspension, the motion of the particles is only determined by the Brownian motion, which 
is depending on the size of the particles. The Stokes-Einstein equation (Equation 2.1) shows the 
relationship between the size of the particles (d) and their translational movement by Brownian 
motion (D). 
 
𝑑 =  
𝑘𝑇
3 ∗ 𝜋 ∗ 𝜂 ∗ 𝐷
 
Equation 2.1 Stokes-Einstein equation. With d being the diameter of the particle, k the Boltzmann constant, T the temperature 
in Kelvin, η the dynamic viscosity and D the diffusion constant representing the translational movement velocity of the 
Brownian motion. 
 
Using that correlation to measure the size of particles works well in general, but can be tricky in some 
situations: Particles have to be spherical and temperature and viscosity of the suspension have to be 
known and set precisely, which can be a problem for complex solvents like cell culture media. 
Furthermore, if particle concentrations of suspensions are too high, scattered light from particles 
might hit other particles in the suspension, scattering again and producing a signal that interferes with 
the measurement, so that a dilution of the sample is necessary.  
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The size of the particles is calculated by an autocorrelation function, which is a mathematical model 
that has to be fed with suitable parameters. The model is built for determining the size of nanoparticles 
in dispersion. The size of monomodal distributions can be determined easily; however, if a particle 
dispersion has multimodal size distribution, it can be difficult in some cases to determine them. For 
example, measuring pure water will always yield a result of some size, as the mathematical model 
expects particles to present in the dispersion. 
However, if all necessary parameters are set and all prerequisites met, the method produces reliable 
results on the diameter of the particles. The size resulting from DLS measurements differs from size 
measurements done by, for example, electron microscopy. This is due to the fact that a particle in 
solution moves with a husk of solvent molecules attached to it. The size of that hull depends largely 
on the adhesion forces between the two materials, but also on chemical stabilizers, if used. Strong 
interactions between solvent and particle usually result in a bigger hull, and thus the actual size of the 
particles is smaller than determined by DLS measurement, where usually the hydrodynamic diameter 
(particle + attached solvent molecules) is determined.[125] This hydrodynamic diameter can increase 
even more, if particles have hairy structures on their surfaces.[126] 
 
Particle Size Measurement using Laser Diffraction (LD) 
Laser diffraction for particle size measurements is based on the wave character of light. If a light beam 
is pointed towards an obstacle with a slit, then after passing the slit, light waves will propagate equally 
in all directions. In case there are two slits in the obstacle, this will happen from both slits. At the point 
where the two waves meet, they will interfere with each other (see Figure 2.1). 
If a light beam hits a particle, the light is diffracted at the particle’s surface. The propagation of light 
waves, after being diffracted on the particle’s surface, is similar as described in the double slit example 
above (see Figure 2.1). The diffracted light waves interfere behind the particle, and thus project a 
characteristic image on the surface of a detector behind the particle. If the size of the particles changes, 
also the diffraction angle changes, and thus the interference of the waves behind the particles is 
different. This can be recognized by the detector and particles of different sizes can be discriminated.  
Calculating a particle size from the scattering image is challenging, as it is not possible to directly use 
the information gained from the scattered light. Usually, the device calculates a result depending on a 
few parameters and matches it with the scattering image. If the match is good enough, it is presented 
as a result to the user, if not: some parameters are changed and a new result is calculated and matched 
again. This will be repeated until a sufficient match can be found. There are commonly two different 
theories that are used for calculations: Fraunhofer theory and Mie theory. Whilst Fraunhofer is easy 
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to apply, it tends to overestimate larger particles. If both, large and small particles, are present in a 
sample, almost only large particles are displayed in the result. Mie theory, on the other hand, works 
well for small and large particles, but it is necessary to know the refraction indices of the particle 
substance, the solvent and the absorption of the particles. Since those variables are difficult to 
determine in some cases (for example for mixtures of a solvent with stabilizers) and since they 
sometimes have big effects on the result, Mie theory can be very difficult to configure properly. 
 
 
Figure 2.1 Laser diffraction and the double slit experiment. 
 
However, Dynamic Light Scattering and Laser diffraction should not be confused with each other. 
While in DLS the motion of a whole particle sample is analyzed, in laser diffraction the scattering image 
of a multiple single particles is taken into account. Laser diffraction thus is more sensitive to the particle 
concentration. Also, measuring particles of non-spherical shape is more problematic, and more 
parameters of the used substance have to be known in LD. Furthermore, the size range in which DLS 
can be used is smaller than for LD, but the method of size calculation has been adjusted for LD, 
depending on the size range of the particles. 
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Zeta potential Measurement with Laser-Doppler Velocimetry 
Particles in dispersion are covered with small husks of their solvent. The thickness of this husk depends 
mainly on the interactions between the particles’ surface material and the solvent. For example, a 
particle with negative charges has a negative electric field around it. The field itself decreases 
quadratically as a function of distance from the particle. Directly where the particle ends, the so-called 
Helmholtz layer (also Stern layer) starts with the inner Helmholtz plane. At the inner Helmholtz plane, 
anions are specifically adsorbed directly onto the surface of the negatively charged particle, due to 
entropic reasons. After a layer of water molecules, the outer Helmholtz plane follows where cations 
are adsorbed non-specifically, due to the attraction of the negative electric field. After the layer of 
cations, a diffuse layer of cations and anions follows. The closer to the particle, the more it consists of 
cations, as the electric field is stronger. Seen from a distant point of view and assuming that the particle 
does not move, it is of neutral charge. If the particle starts to move, friction is applied to it and to all 
the ions in its area of influence. In the outer region, the friction will be stronger than the electric field 
of the particle, and ions will be sheared off the particle. The area, right where the shearing ends, is 
called the shearing plane, and the electric potential of the electric field of the particle at this point is 
defined as the zeta potential for the measurement with the device (Malvern Zetasizer Nano ZS) used 
in this thesis.[127] 
During a zeta potential measurement, the particles are being moved by an electric field applied to the 
sample. This effect is called electrophoresis; The Henry equation (Equation 2.2) explains how 
electrophoretic mobility UE is related to the zeta potential z.[127] 
 
𝑈𝐸 =  
2 ∗  𝜀 ∗ 𝑧 ∗ 𝑓(𝑘𝐴)
3 ∗  𝜂
 
Equation 2.2: The Henry Equation shows the dependencies between the electrophoretic mobility UE, the dynamic viscosity of 
the medium (η), the dielectric constant (ε), the zeta potential z and Henry’s function f(kA). Values of f(kA) are commonly either 
1.5 for particles down to approximately 200 nm in aqueous medium or 1 for small particles in low-salt (organic) medium. 
 
The movement of the particles is measured by Laser Doppler Velocimetry: A laser beam is pointed at 
the moving particles. Upon contact of the laser beam and the moving particles, the frequency of the 
laser beam changes proportionally to the velocity of the moving particles. Scattered light of the 
frequency-changed laser beam goes to the detector, together with a reference beam that did not pass 
the sample and is thus unchanged.[128] The comparison of waves from both beams can be used to 
calculate the velocity of the particles, and thus by Henry’s equation also their zeta potential. By the 
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orientation of the shift in the wave pattern, it can be determined whether the zeta potential is positive 
or negative. 
High Pressure Liquid Chromatography (HPLC) 
High Pressure Liquid Chromatography (HPLC) is one of the most common chromatographic methods 
in laboratory use. A liquid phase (mobile phase) is pressed through a column filled with a solid phase 
(stationary phase). Molecules within the mobile phase, interacting with the stationary phase, stay on 
the column for a longer period of time. Thus, substances can be separated by their different attraction 
forces to the solid phase. HPLC devices usually have a pump that pumps the mobile phase through a 
column containing the stationary phase. There is an injection loop for loading a small amount of sample 
(usually between 5 µl and 20 µl) into the running mobile phase. The mobile phase carries the sample 
through the column, where it is separated into its components by attraction forces to the stationary 
phase. After passing the column, the sample is carried by the mobile phase through a detector. 
Cation and anion exchanging columns exist as solid phases, but most common are reverse phase 
(separation through hydrophobic interactions) columns. These columns usually have alkyl groups 
tightly packed on dextran beads with different chain lengths, depending on their purpose. For 
separating small molecules or peptides, often C18 alkyl group-columns are used, as it is the case in this 
thesis. For bigger substances, such as proteins, often C4 columns are the subject of choice. Detection 
of a substance depends on the characteristics of that substance. There are different kinds of detectors, 
like for example flame ionization or UV/Vis detectors that can determine different properties of a 
component. As UV detectors, like they were used in this thesis, detect non-selectively, they have to be 
adjusted to a wavelength where the desired component exhibits absorption. A control run with only 
the desired substance is necessary to discriminate the substance’s peak from others in the 
chromatogram. A quantification of the substance can be done by an integration of the peak and a 
comparison with a respective standard curve. 
 
Mass Spectrometry 
Mass spectrometry is a method to analyze each compound in a mixture. The mass spectrometer ionizes 
the species and then separates and detects them by a mass to charge ratio (usually denoted by “m/z 
ratio”). In an ideal case, every component in a mixture has its unique mass to charge ratio and can thus 
be identified properly. However, mass spectrometers have a very high resolution and can determine 
differences of single Dalton weight in molecules. Therefore, every compound comes with distribution 
of different weights according to its isotopes. Also, ionization products sticking to compounds, 
fractured compounds and non-fully ionized compounds make the mass spectrum less clear. 
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The mass spectrometer always consists of three main units: The ion source/accelerator, the analyzer 
and the detector. The ion source ionizes the compounds, which results in an individualization of all 
molecules due to the high charge. The accelerator then accelerates them within an electric field. The 
ions then move through the analyzer, where they are separated by their mass to charge ratio, and 
finally they hit the detector. The detector only determines the intensity (amount) of a component 
hitting it. Combining that information with the parameters of the analyzer at the same time point, 
results in an intensity peak at a certain mass to charge ratio in the spectrum. 
For the analysis of a compound, often a liquid chromatography like HPLC is directly coupled to a mass 
spectrometer, such that a compound mixture is separated before it is ionized and accelerated. This 
helps identifying substances that have numerous peaks in a mass spectrum and come from a mixture 
of substances. 
 
Membrane emulsification 
Membrane emulsification is a method to prepare emulsions with the help of a filter membrane. Two 
phases, aqueous and organic/oily, are separated by a glass membrane with a certain pore size. A gas 
pressure is applied to the dispersed phase, and thus presses it through the membrane. The other phase 
(continuous phase) is stirred and rips off droplets of the dispersed phase coming through the 
membrane (see Figure 2.2). If the dispersed phase is hydrophilic, then the membrane should be 
lipophilic to avoid droplets from mixing on the membrane surface after they have been pressed 
through the membrane. Also, higher level emulsions, like for example oil in water in oil, are possible, 
if the dispersed phase is already an emulsion and the pore size of the membrane is suitable. The size 
of the produced emulsion droplets depends on the pore size of the membrane and can be explained 
by Equation 2.3. The parameter ‘a’ is a constant, usually depending on the kind of the membrane and 
other experimental conditions. In most cases, ‘a’ lies within a range of 2.5 to 8.[129] 
 
𝐷𝑟𝑜𝑝𝑙𝑒𝑡_𝑆𝑖𝑧𝑒 = 𝑎 ∗ 𝑃𝑜𝑟𝑒_𝑆𝑖𝑧𝑒 
Equation 2.3: Linear relationship between pore size and droplet size in membrane emulsification. 
 
The pressure needed to press the dispersed phase through the membrane varies according to several 
parameters. The Hagen-Poiseuille equation (Equation 2.4) reveals the length of the pore, the diameter 
and viscosity to be relevant. 
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𝑝𝑏𝑒𝑔𝑖𝑛𝑛𝑖𝑛𝑔 𝑜𝑓 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 =  
8 ∗ 𝑉𝑓𝑙𝑜𝑤 ∗ 𝜂 ∗ 𝐿
𝜋 ∗  𝑟4
+ 𝑝𝑒𝑛𝑑 𝑜𝑓 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒  
Equation 2.4: Hagen-Poiseuille Equation: Vflow being the volume flow through the pore, η being the dynamic viscosity, L the 
length of the pore, r being the radius of the pore and p being the pressure. 
 
However, the Hagen-Poiseuille equation leaves out, for example, the pressure loss by friction caused 
by interactions between dispersed phase and membrane. If the membrane and the dispersed phase 
have a high interface tension, then this parameter has to be considered and pressure can be calculated 
by the Darcy-Weisbach Equation (Equation 2.5). 
 
𝑝𝑏𝑒𝑔𝑖𝑛𝑛𝑖𝑛𝑔 𝑜𝑓 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 =  𝜆 ∗  
𝐿
𝑑
∗ 
𝜌
2
∗ (
𝑉𝑓𝑙𝑜𝑤
𝐴
)
2
+  𝑝𝑒𝑛𝑑 𝑜𝑓 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 
Equation 2.5: Darcy-Weisbach equation: λ being the Darcy friction factor formulae giving the actual friction value depending 
on the materials involved, L being the length and d being the diameter. ρ denotes the density of the fluid, Vflow the volume 
flow through the pore, A the area cross-section and p the pressure. 
 
The surface of the membrane inside the pores is exposed to the fluid. Considering that volume scales 
by sixth power and area only by forth power in the equation, it can be assumed that choosing 
membranes with larger or smaller pores, and thus the Darcy friction factor, will result in a quadratic 
change in necessary pressure to overcome the membrane. 
A further problem to these considerations is, that both equations assume the pore to be a single pipe; 
however, in most cases, as well as in the membranes used for this thesis, pores are branched and have 
obstacles, such that laminar flows are not necessarily given. Usually, required pressures are much 
higher than what can be calculated by Equation 2.4 and Equation 2.5. Furthermore, in all cases polymer 
solutions of much higher viscosities than plain water were pressed through membranes. A 
determination of necessary pressures was therefore conducted by experience rather than by 
calculation. By starting a membrane emulsification, fluids do not directly move through the membrane, 
as there is a liquid limit. A certain initial pressure that overcomes the limit has to be reached, in order 
to start the flow of dispersed phase through the membrane. The manual of the device used in this 
thesis (External Pressure Type Micro Kit, SPG Technology Co, Ltd., Miyazaki, Japan) suggested a 
membrane pre-wetting, with continuous phase and stabilizers to lower that limit.  
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Figure 2.2: Scheme explaining the process of membrane emulsification. A pressure is applied to the dispersed phase (blue). 
Smaller amounts of the aqueous solution pass the membrane into the stirred alkane, usually pentane (yellow), with stabilizers. 
The stirring force pulls smaller droplets (light blue) off the membrane for emulsion formation. 
 
An enormous advantage of the membrane emulsification is, that the energy is only applied in form of 
pressure on one of the liquid phases. Since liquid phases are not compressible, none of this pressure 
is applied to an API dissolved in the liquid phase. Forces are only applied to the API in form of shear 
forces when passing the membrane. 
 
Ultrasound sonication 
Sonication is the use of sound to apply energy to a system. In most cases, ultrasound is used, as sound 
of lower frequencies is not potent enough for most applications. Ultrasound sonication can be used to 
mix substances, redisperse particles, clean surfaces, prepare emulsions and many more things. In 
pharmaceutical nanotechnology, it plays a major role for the redispersion of aggregated particles and 
the preparation of emulsions. The high-frequency sound waves generate cavities from dissolved gas, 
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which form and implode. Upon implosion, shear forces are generated, that can lead to an 
emulsification or redispersion of particles. The presence of stabilizers then keeps the developed 
emulsion or redispersed particles stable. For particle dispersions, usually ultrasound baths are used 
that typically have frequencies around 40-400 kHz. The lower the frequency, the stronger is the effect 
of cavitation, thus the higher frequent mode is important for ultrasound baths, if for example 
compounds are supposed to be cleaned gently. Ultrasound probes have single frequencies of 
operation – usually between 20 and 40 kHz. The probe used in this thesis oscillated at 20 kHz. The 
strong energy of an ultrasound probe also produces a lot of heat energy, such that a constant cooling 
(for example sonication on ice) is beneficial. This applies especially, if sensitive biologicals are 
involved.[130, 131] 
 
Lyophilization 
Lyophilization, also called freeze drying, is a method to extract a volatile component (usually a solvent) 
from a sample, leaving only the non-volatile components as dry powder. In most cases, it is used to 
remove water from samples. For that purpose, the sample is frozen first, and then a negative pressure 
is applied to sublimate the volatile substance into its gaseous state (see purple arrows at Figure 2.3). 
This results in a removal of the water, which has the advantage that the liquid phase is not passed and 
water sublimates directly from the solid state. Lyophilization can also be done with organic solvents, 
but as freezing points of organic solvents are lower than water, all processes have to be executed at 
lower temperatures as done with acetonitrile in this thesis. 
 
Figure 2.3: Phase diagram of water with arrows indicating lyophilization. First, temperature is decreased to freeze the sample 
(horizontal arrow), then pressure is reduced to sublimate the volatile component (vertical arrow). 
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Scanning Electron Microscopy 
As nanoparticles are very small in size, visible light with wavelengths longer than the size of the 
nanoparticles does not qualify for imaging. Nanoparticles with sizes of around 130 nm, as described in 
this thesis, can be imaged with electron microscopy, because the wavelength of electrons is much 
shorter (approximately 10-3 nm).[132] For electron microscopy, an electron source (usually a tungsten 
or lanthanum hexaboride filament) is placed above a sample. Upon charging the filament, electrons 
are emitted towards the sample. The electron ray is accelerated and modified by several lenses that 
change its focus and magnification. Upon hitting the sample, electrons interact with the outer electron 
shells, and secondary electrons are emitted. These are caught by a detector and they are interpreted 
as an intensity signal. The electron beam scans over the whole image line by line, such that the electron 
ray is always focused on a single spot, as in contrast to light microscopy, where every part of the image 
is mapped at the same time. Differences in the intensity of reflection/absorption of electrons on the 
sample create different intensities, brighter or less bright, on the image. A very strong electron ray can 
change the sample, especially in case of biological and less solid chemical samples. Particles made of 
polysaccharides often exhibit a glowing pattern that can disturb the imaging process, because they are 
charged by the electron ray. Since most biological samples do not emit a lot of secondary electrons, 
they are usually sputter coated with a layer of metal, usually gold or platinum, of few nanometers 
thickness. These metals emit enough secondary electrons to make the shape, to which they were 
sputtered, visible, and they can dissipate the electron ray.  
 
Thermogravimetric analysis 
Thermogravitmetric analysis (TGA) is conducted to measure changes in weight during heating. This 
usually happens when there is evaporation, sublimation, degradation or loss or gain of mass, by for 
example reduction or oxidation. A common application is to determine amounts of crystal water 
remaining in samples. In case of polymers as used in this thesis, the degradation of the polymer has to 
be determined beforehand, to at which point a weight loss is not due to evaporating water. In case of 
this thesis, TGA was used to determine the dry weights of particles’ samples for the calculation of 
loading efficiencies. 
 
Confocal Laser Scanning Microscopy (CLSM) 
CLSM is a technology featuring an optical microscope taking pictures enhanced by fluorescence. In 
principle, CLSM microscopes work like normal fluorescence microscopes. A laser is pointed at a 
fluorescing sample and activates it. The light emitted from the sample goes through a filter that only 
allows fluorescing light to pass, not the exciting laser light. In this way, fluorescence of a sample can 
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be visualized. The difference to an ordinary fluorescence microscope is, that the laser of a CLSM can 
be focused very precisely, such that fluorescence information can be gathered not only from broad 
points in X and Y axis but also from within the sample (in Z axis). Thus, the excited volume is very small 
and different sections within one sample can be excited separately. This allows, for example, to show 
if certain fluorescing substances are within a larger object or just on its surface. A problem, 
nevertheless, is that the exciting and the emitting lights have to travel through the whole sample. That 
can lead to weaker excitations and bleaching outside the focal plane, and to absorption of emitted 
light by the sample. 
 
2.2.2 PLGA particle preparation and characterization 
Nanoparticles were chosen as drug delivery system, as small particles could be able to bypass biological 
barriers easier than larger particles in the micrometer range. Furthermore, a hydrophilic system would 
not be suitable, as it would dissolve before it could pass the barrier. Therefore, hydrophobic PLGA 
nanoparticles were chosen, which are well-characterized in literature for the encapsulation of various 
therapeutic substances (see section 1.2.1). A commonly used preparation method was employed and 
adjusted for our purposes. 
 
PLGA particle preparation -- Double Emulsion Solvent Diffusion Centrifugation – method 
PLGA nanoparticles were prepared by a modified double emulsion solvent diffusion centrifugation 
method. For one batch, 50 mg of PLGA were dissolved in 1.5 mL of ethyl acetate and mixed with 0.5 
mL of an aqueous solution. The composition of the aqueous solution differed depending on the batch. 
It contained either the drug (500 µg of desmopressin) and a stabilizer (6.25 mg) or only the drug, or 
nothing (see Table 2.1). For the coating approach, blank PLGA nanoparticles (inner emulsion was MQ 
water only) were prepared as described above. After the volume had been adjusted to 20 mL, 500 µg 
of desmopressin was added. The solution was kept at room temperature (RT) for 15 min before the 
centrifugation step (as for all other samples). The mixture of both was then sonicated for one minute 
with approximately 800 J to produce the primary emulsion. After the primary emulsion had formed, 
another 2.5 mL of aqueous PVA solution (25 mg/mL) were added, and the whole was sonicated again 
for one minute with approximately 800 Joule to form the secondary emulsion. Afterwards, 
approximately 15.5 mL of MilliQ (MQ) water were added to precipitate the particles from the emulsion. 
The volume was adjusted to exactly 20.0 mL. For removing the ethyl acetate, samples were filled into 
Eppendorf tubes in quantities of 1 mL and centrifuged for 25 min at 24 kRCF and 16 °C. After 
centrifugation, the supernatant was discarded and the remaining pellet was rinsed with one mL of MQ 
water. After rinsing the pellet, all water was poured out, but some water remained in the tube sticking 
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to the plastic walls. The tubes were kept for several hours, in which the remaining water formed a 
droplet and dispersed the pellet. From this point on, the particles could be used for analysis. 
A coating approach (CT), where the particles were coated with desmopressin instead of an 
incorporation, was used for comparison. For the coating approach, blank PLGA nanoparticles (inner 
emulsion was MQ water only) were prepared as described above. After the volume had been adjusted 
to 20 mL, 500 µg of desmopressin was added. The solution was kept at room temperature (RT) for 15 
min before the centrifugation step (as for all other samples). 
 
Table 2.1 Different configurations of the primary emulsions 
Tag Substances Description 
BK None (only MilliQ water) blank particles 
CT None (only MilliQ water) particles for desmopressin coating 
PL Desmopressin (500 µg) no stabilizer in the prim. emulsion 
PVA PVA (12.5 mg/mL), desmopressin (500 µg) PVA as stabilizer 
PEG PEG 400 kDa (12.5 mg/mL), desmopressin (500 µg) PEG as stabilizer 
TW21 Tween 21 (12.5 mg/mL), desmopressin (500 µg) Tween 21 as stabilizer 
F68 Pluronic F-68 (12.5 mg/mL), desmopressin (500 µg) Pluronic F-68 as stabilizer 
F127 Pluronic F-127 (12.5 mg/mL), desmopressin (500 µg) Pluronic F-127 as stabilizer 
 
PLGA particle dissolution 
Eppendorf tubes with PLGA particles were prepared as described above. To dissolve the particles, 400 
µl of acetone were added to PLGA particles, dispersed in the rinsing water droplet from their 
preparation. The particles were kept in acetone for at least two hours. After that time, 1600 µl of 
ethanol were added to the solution. The ethanol precipitated the PLGA with desmopressin staying in 
solution. The tubes were then centrifuged (24 kRCF, 40 min, 4 °C) to condense the precipitated PLGA 
into a pellet. The supernatant, containing no PLGA but the desmopressin, was transferred to a new 
tube where it was left to evaporate overnight under a hood. After ethanol and acetone evaporation, 
only desmopressin was left in the tube. One milliliter of MilliQ water was then added to the tube to 
dissolve the desmopressin for analysis. 
 
Dry weight analysis for loading efficiency 
Eppendorf tubes of one milliliter washed particle dispersion were frozen at - 80 °C and then freeze 
dried for two days in a Christ Alpha 2-4 LSC (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode 
am Harz, Germany). The freeze-dried particles of one tube were then put into a device for 
thermogravimetric analysis (Perkin Elmer TGA 4000, Waltham, Massachusetts, USA) to remove any 
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remaining water by heat. The weight at 160 °C, which is shortly before PLGA degradation temperature 
(i.e. approx. 180 °C), was determined as dry weight of the particles. 
 
Desmopressin quantification by HPLC 
A Dionex Summit HPLC System with a P680 gradient pump and a Dionex Ultimate 3000 UV/Vis detector 
was used to quantify amounts of desmopressin from dissolved particles. The column was an 
endcapped reversed phase LiChrospher® LiChroCart® 125-4 RP-18e (5µm) column with a LiChrospher® 
RP-18e (5µm) guard column, both Merck KGAA (Darmstadt, Germany). The mobile phase consisted of 
50 mmol KH2PO4 buffer (pH 7.2), mixed with acetonitrile in a 80:20 (v/v%) ratio in an isocratic elution 
mode. The column was kept at 30 °C and the injection volume was 50 µL. Usually, the desmopressin 
peak could be seen in the chromatogram at around 6 min, and quantification was done by peak 
integration. 
The encapsulation efficiency and the loading efficiency of desmopressin were defined and calculated 
as: 
 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛_𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 [%] =  
𝐴𝑚𝑜𝑢𝑛𝑡_𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑_𝑓𝑟𝑜𝑚_𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 [µ𝑔]
𝑇𝑜𝑡𝑎𝑙_𝑎𝑚𝑜𝑢𝑛𝑡_𝑢𝑠𝑒𝑑_𝑑𝑢𝑟𝑖𝑛𝑔_𝑝𝑟𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛 [µ𝑔]
∗ 100% 
Equation 2.6: Calculation of encapsulation efficiency. 
 
and: 
 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔_𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 [
µ𝑔
𝑚𝑔
] =  
𝐴𝑚𝑜𝑢𝑛𝑡_𝑜𝑓_𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑟𝑒𝑡𝑟𝑖𝑒𝑣𝑒𝑑_𝑓𝑟𝑜𝑚_𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 [µ𝑔]
𝑇𝑜𝑡𝑎𝑙_𝑚𝑎𝑠𝑠_𝑜𝑓_𝑡ℎ𝑒_𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 [𝑚𝑔]
 
Equation 2.7: Calculation of loading efficiency. The loading efficiency was used for the comparison between the different 
stabilizers. It is calculated by the division of the amount of peptide retrieved from the particles by the amounts of polymer, 
peptide and remaining stabilizers summed together (i.e. total mass of the formulation). 
 
Size and zeta potential measurements 
Size and zeta potential of particles were measured with a Zetasizer Nano ZS or ZSP (Malvern 
Instruments GmbH, Herrenberg, Germany). Particle pellets were redispersed in MilliQ water. pH values 
of the particle suspensions were measured, and then 1:10 dilutions (with MilliQ water) were measured 
for size (173 ° backward scatter mode) and zeta potential (13 ° forward scatter mode). 
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Desmopressin integrity analysis  
The integrity of the desmopressin after encapsulation and dissolution of the particles was checked 
with a liquid chromatography coupled electrospray ionization mass spectrometer (LC-ESI-MS). An 
Accela UHPLC system (Thermo Fisher Scientific, Waltham, MA, USA) with a built-in degassing system 
and a quaternary mixing pump was used. It was coupled to a Thermo Scientific TSQ Quantum Access 
Max mass spectrometer. Detection was performed by a full scan acquired from m/z 15 to 1100 after 
Electrospray-Ionization in positive ion mode. 
 
Particle imaging 
SEM images of particles were made with a Zeiss Evo HD 15 Electron Microscope (Carl Zeiss AG, Jena, 
Germany) and coated with approx. 10 nm gold with a Quorum Q150R ES sputter coater (Quorum 
Technologies Ltd., East Grinstead, UK) or with a Hitachi S-510 (Hitachi, Chiyoda, Japan) with an 
integrated DISS 5 image converter (point electronic, Halle (Saale), Germany). Samples were coated 
with gold in an Edwards S150 sputter coater (Edwards, Crawley, UK). 
Confocal microscopy was conducted with a Zeiss Axiovert 100M (Carl Zeiss AG, Jena, Germany). For 
excitation, an argon laser from Coherent Inc. (Santa Clara, CA, USA) with 488 nm wavelength was used. 
Emission was detected with a BP filter of 505-530 nm wavelength. 
 
PLGA-particle coating with human lactoferrin peptide (hLF) for barrier permeation enhancement 
The hLF-peptide was dissolved in a KH2PO4 buffer and incubated at 37 °C for 2 hours to form disulfide 
bonds. Blank PLGA nanoparticles were prepared as described above. One mL of particle dispersion was 
placed in an Eppendorf tube (n = 3) and centrifuged (24 kRCF, 20 min, 16 °C). The supernatant was 
discarded and particles were washed with pure MQ water. The redispersed particles were then 
incubated with KH2PO4 buffer and hLF-peptide for 2 hours. After incubation, the sample was 
centrifuged again (24 kRCF, 20 min, 16 °C). The supernatant was removed, but not discarded and stored 
for analysis. The pellet was washed with MQ water and the redispersed particles were taken up in 2 
mL KH2PO4 buffer and left at room temperature for 7 days. Samples were analyzed on day 0 (i.e. day 
of preparation), 1, 2, 3, 4 and 7. 
For analysis, 100 µL of sample were taken and mixed with 900 µL of MQ water. The sample was 
analysed for pH and zeta potential. Another 200 µL were taken and put in an Eppendorf tube. The 
Eppendorf tube was centrifuged (24 kRCF, 20 min, 16 °C), particles and supernatant were separated 
and both measured with a QuantiPro™ BCA Assay Kit (Sigma Aldrich, Taufkirchen, Germany). The pellet 
was washed once with MQ water and then redispersed in 200 µL MQ water. BCA solution was prepared 
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according to the manual and 150 µL were mixed with the samples (either 150 µL of supernatant or 
particle dispersion) in a 96-well plate. The plate was incubated for 2 hours at 37 °C and then analyzed 
with the TECAN® Reader Infinite 200 PRO (Tecan Group Ltd., Männedorf, Switzerland) at a wavelength 
of 562 nm. All retrieved values were zeroed to comparing solutions. Therefore, plain particle dispersion 
without hLF-peptide (for particle dispersion), pure buffer (for supernatants) and pure water (for 
standards) were measured as well. 
 
2.2.3 Hydrophilic particle preparation 
As nanoparticles cannot be sufficiently delivered into the deep lung via inhalation, the PLGA particles 
had to be encapsulated into microparticles; however, for a local application in the lungs, or if the drug 
passed the lung barrier on its own, PLGA nanoparticles would be an unnecessary step, as the drug 
could be directly loaded into microparticles. If, on the other hand, a drug would not work well with the 
microparticulate carrier or needed a functionalized delivery vehicle, a combination of the two systems 
could be necessary. Thus, a new, versatile method was developed that allowed encapsulation of 
functionalized hydrophobic nanoparticles, as well as direct encapsulation of hydrophilic drugs for the 
delivery to the deep lung. Furthermore, it was a goal to be able to adjust the size of the particles as 
well as the hydrophilic polymer that was to be used. In most cases, dextran was used as hydrophilic 
polymer because it is used as a blood plasma expander [51] and thus has a good solubility in water, it is 
compatible with the human body.  
 
Preparing emulsions by membrane emulsification 
An “External Pressure Type Micro Kit” fabricated by SPG Technology (Miyazaki, Japan) was used for 
membrane emulsification. If not stated otherwise, hydrophobic glass membranes with a pore size of 
0.5 µm diameter were used for emulsification. The dispersed phase was 2 mL of a 10 wt% dextran (150 
kDa) (Sigma Aldrich) in aqueous solution. The continuous phase was pentane mixed with 0.25 vol% 
Span 80 and Tween 85 each (Sigma Aldrich). It was used in quantities of 80 mL pentane in a 100 mL 
beaker (50x70 mm) with a magnetic stirring rod (40x8 mm) at 400 RPM. The applied pressure to the 
dispersed phase was nitrogen at 2 bar. Runs were conducted until gas bubbles were floating up from 
the membrane, indicating that all aqueous solution had passed the membrane. 
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Table 2.2 Overview of membrane emulsification experiments. (Each experiment: n = 3) 
Experiment # Inner phase Outer phase 
 
# 1 
10 wt% dextran Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 2 
10 wt% dextran 
+ 0.1 wt% Pluronic F-127 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 3 
10 wt% dextran 
+ 1.25 wt% Pluronic F-127 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 4 
10 wt% dextran 
+ 5 wt% Pluronic F-127 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 5 
10 wt% dextran 
 
Liquid paraffin 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 6 
2.5 wt% chitosan (Novamatrix Protasan) 
(see description below) 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
In Experiment # 6 a 2.5 wt% chitosan solution was used as inner phase. To produce more homogenous 
small emulsion droplets, multiple membrane cycles were used. First, the emulsification was carried 
out in the same way as for all other experiments. After that, it was left to sediment for at least 15 
minutes. The sedimented droplets on the bottom of the beaker were collected with a pipette. The 
collected droplets were then used for the next cycle of membrane emulsification. Thus, they were put 
into the membrane emulsification device and pressed through the membrane into the continuous 
phase again to further homogenize the emulsion. For all cycles after the first, a pressure of about 5 bar 
was necessary. This procedure was repeated three times. 
 
Preparing emulsions by high shear homogenizer method 
For preparing emulsions with the high shear homogenizer, an Ultra Turrax® with a T25 base unit was 
used with an 18G rotor-stick (IKA®-Werke GmbH & Co. KG, Staufen, Germany). 80 mL of continuous 
phase (the same that was used for the membrane emulsification method) was directly mixed with 2 
mL of dispersed phase (water with dissolved hydrophilic polymer) and emulsified in a 100 mL glass 
bottle. Homogenization was conducted at 16,000 RPM for 10 seconds. 
 
 
 
40 
 
Table 2.3 High shear homogenizer experiments overview. (Each experiment: n = 3) 
Experiment # Inner phase Outer phase 
 
# 7 
10 wt% dextran Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 8 
2.5 wt% chitosan (Novamatrix Protasan) 
 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 9 
1 wt% alginate 
 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 10 
1 wt% glucomannan 
 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 11 
2.5 wt% gelatin 
 
Pentane 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
# 12 
1 wt% lignin 
NaOH was added until Lignin dissolved 
Liquid paraffin 
+ 0.25 vol% Span80 
+ 0.25 vol% Tween85 
 
Precipitation and particle formation 
For particle preparation, the polymer in the emulsion droplets was precipitated. Therefore, 5 mL of 
the emulsion (prepared either by membrane emulsification of by high shear homogenizer method) 
were taken up into a 10 mL plastic syringe. The syringe was equipped with a 0.6 mm diameter needle 
and mounted into a syringe pump (kd Scientific Legato 210, Holliston, MA, USA). The mounted 
syringe/needle was placed in 40 mL of ethyl acetate residing in a 100 mL beaker being stirred at 400 
RPM with a magnetic stirring rod (40x8 mm). The syringe pump then injected the emulsion into the 
stirring ethyl acetate at a speed of 1 mL/min. Upon mixing, both, the outer phase of the emulsion 
(usually pentane with stabilizers) and the water of the inner phase, mixed with the ethyl acetate. The 
hydrophilic polymer (usually dextran) precipitates and forms particles as displayed in Figure 2.4. 
 
Washing and solvent exchange 
The precipitated particles were washed by taking the dispersion up into a syringe and pressing it 
through a syringe filter equipped with 100 nm pore size PTFE membrane. The solvent mixtures easily 
passed the membrane, whilst particles were retained. To wash off remaining solvents and stabilizers 
from the particles, 10 mL of pure ethyl acetate were pushed through the syringe filter. Afterwards, 
particles were redispersed by adding fresh ethyl acetate that was sucked up through the syringe filter 
from the other side, carrying the particles back into the syringe (similar as seen in Figure 2.5). 
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Afterwards, a solvent exchange from ethyl acetate to acetonitrile was carried out for lyophilisation. 
Therefore, 5 mL of acetonitrile were pushed through the syringe to remove the ethyl acetate remaining 
in the syringe filter, then 10 mL of acetonitrile were sucked through the syringe filter, carrying the 
particles into the syringe as displayed in Figure 2.5. 
 
 
Figure 2.4 Schematic explanation of the precipitation process. Ethyl acetate is displayed in green, water in blue, pentane in 
yellow and pure dextran in white. 
 
 
 
Figure 2.5: Schematic explanation of the solvent change by syringe and syringe filter. Ethyl acetate is displayed in green, 
another solvent, like for example ethanol or acetonitrile, is displayed in purple. Particles are displayed as white dots.  
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Size measurements 
Sizes of microparticles were measured before washing in ethyl acetate with a Horiba LA-950 (Retsch 
GmbH, Haan, Germany). Calculation of the results was done with Mie-Theory using refractive indices 
of 1.530 for the solid phase and 1.371 for the liquid phase ethyl acetate. 
 
Lyophilisation and drying 
For lyophilisation, particles were washed and solvent was exchanged from ethyl acetate to acetonitrile, 
as described above. The dispersion was then put into glass vials with small holes in their lids. The 
acetonitrile was frozen by immersion of the lower half of the glass vials into liquid nitrogen for roughly 
30 seconds. The glass vials were then placed in the pre-frozen freeze drier (Christ Alpha 2-4 LSC, Martin 
Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) at -80 °C condenser (and about 
-35 °C shelf) and a negative pressure of 0.2 mbar was applied. In every run, a maximum of 6 vials were 
placed in the freeze drier and left for 48 hours to sublimate acetonitrile. After retrieving the glass vials 
from the freeze drier, the holes in the lids were closed with tape to avoid additional air humidity 
entering the vials. 
 
Direct encapsulation of desmopressin into dextran microparticles 
For preparing the microparticles, 300 mg of Dextran were mixed with 1 mg desmopressin acetate in 1 
mL of MQ water. Additionally, 500 µg of Pluronic F-68 were added. The mixture was then emulsified 
by membrane emulsification into pentane with 2.5% Span85 as stabilizer. Sediment substance was 
removed and the pentane of the remaining emulsion was removed by evaporation, until the emulsion 
was entirely in Span85. Then 25 mL of ethyl acetate with 10 mg/mL PEG were added to precipitate the 
emulsion droplets. The dispersion was stirred for 5 minutes and then centrifuged at 5000 RPM for 10 
minutes in 50 mL tube vials. The supernatant was discarded and 20 mL of fresh ethyl acetate were 
added to wash the particles. After particle redispersion, it was centrifuged as above and the 
supernatant was removed. The wet particles were left to dry overnight under a hood. Analysis was 
conducted by HPLC: 5 mg of particles powder were dissolved in 1 mL of MQ water and analyzed as 
described in section 2.2.2. 
 
Long-term stability 
For checking long-term stability, the particles were stored at room temperature in sealed vials 
containing air atmosphere. After at least 11 months, SEM images of the particles were taken again for 
comparison. 
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2.2.4 Combination of PLGA and hydrophilic particles 
Nanoparticles, as described in section 2.2.2, do not face impaction or sedimentation when applied to 
the lung, as those are only relevant above 1-2 µm. Below 1 µm, most particles reach the deep lungs 
but are exhaled again, with particles around 250 nm size having the worst deposition rates. At around 
200 nm size and smaller, deposition improves due to diffusion effects.[96] However, separating single 
100–150 nm sized particles for a pulmonary application can be challenging, such that a combined 
approach was chosen for this thesis. 
The hydrophilic particles described in section 2.2.3 have the potential to deliver a payload to the deep 
lung, if prepared with the right aerodynamic properties, but they would most likely immediately 
dissolve, so that a controlled release over time or an enhanced barrier penetration would be 
impossible. A combined approach of both systems could be a solution to these problems. The drug 
could be encapsulated into functionalized PLGA nanoparticles and then packed into hydrophilic 
microparticles that reach the deep lung and release the nanoparticles there. The microparticles would 
dissolve quickly after transporting the nanoparticles to the deep lungs. The released nanoparticles 
could then mediate the transport through the lung barrier. 
 
Preparation of PLGA nanoparticles for encapsulation into dextran microparticles 
PLGA nanoparticles were prepared from PLGA, covalently coupled with fluorescein-amine (FA-PLGA). 
The particles were prepared in the same way as described in section 2.2.2, with the difference that no 
primary emulsion was used. I.e. FA-PLGA dissolved in ethyl acetate was directly mixed with aqueous 
PVA solution and sonicated (see Figure 2.6). After preparation, the particle suspension was adjusted 
to 20 mL volume, and 1 mL of it was centrifuged in an Eppendorf tube (24 kRCF, 25 min, 4 °C). The 
supernatant was discarded, and the pellet was rinsed with MQ water and then redispersed in 1 mL MQ 
water. 
 
Preparation of dextran microparticles loaded with FA-PLGA nanoparticles 
The preparation of dextran microparticles followed the description in section 2.2.3 experiment # 1, 
with the difference that the stabilizers used in the outer phase were 1.25% of Span 85 and Brij O2 each, 
instead of the described 0.25% of Span 80 and Tween 85, and the glass membrane had a pore size of 
2 µm instead of 0.5 µm. For the emulsification, 2 mL of 10% dextran (20 kDa) solution were prepared 
and 0.5 mg of FA-PLGA nanoparticles were added. Then the membrane emulsification was carried out 
with the PLGA nanoparticles in the dispersed phase. After the emulsification, the emulsion was left to 
evaporate roughly half of its volume to increase the droplet concentration. Precipitation was carried 
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out by hand instead of a syringe pump, all other parameters (volumes etc.) remained the same. 
Following that, 20 mL of the precipitated suspension were pressed through a 100 nm pore diameter 
PTFE filter membrane retaining the particles. The membrane was rinsed with 10 mL of ethanol, and 
thus the particles were brought back into ethanol. A few drops of this sample were dropped on a glass 
slide for CLSM analysis. A cover glass was directly put on top to prevent the evaporation of ethanol 
and drying of the sample, as the small 20 kDa dextran particles would instantly dissolve in air humidity, 
due to their hygroscopic nature. 
 
 
Figure 2.6: Preparation of FA-PLGA-NP loaded dextran microparticles for CLSM examination. 
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3 Results and Discussion 
3.1 PLGA nanoparticles 
This part will deal with the results of the preparation of hydrophobic PLGA nanoparticles, as well as 
with the encapsulation of desmopressin, its integrity after encapsulation, and the coating of the PLGA 
nanoparticles with hLF-peptide. Parts of the data shown have already been published by Primavessy 
et al.[38] 
 
3.1.1 Characterization of PLGA nanoparticles 
The PLGA nanoparticles, prepared as described in section 2.2.2, had sizes of 106-130 nanometers with 
small deviations (< 2 nm) in their triplicates. The PDI values were all well below 0.05; therefore, a 
monomodal distribution of particles can be assumed.[133] Zeta potentials were measured with values 
between -35 and -44 mV, which indicates, together with low PDIs, a stable dispersion. The pH values 
of all preparations were similar and lied between 5.5 and 6 (see Table 3.1).  
 
Table 3.1: Sizes, PDI values, zeta potentials and pH values of the prepared particles. (Mean values, each experiment: n = 3) 
 Size [nm] PDI Zeta potential [mV] pH Value 
 Mean Dev Mean Dev Mean Dev Mean Dev 
BK 131.37 1.07 0.02 0.01 -44.36 2.81 5.65 0.06 
CT 130.40 1.42 0.05 0.01 -39.03 3.82 5.56 0.05 
PL 126.17 1.70 0.05 0.02 -38.64 2.26 5.82 0.54 
PVA 125.64 1.77 0.02 0.01 -35.92 3.51 5.91 0.15 
PEG 128.33 1.29 0.01 0.01 -40.70 1.67 5.91 0.03 
TW21 106.32 1.66 0.08 0.03 -43.73 2.06 5.56 0.03 
F68 119.14 0.94 0.05 0.01 -40.59 1.92 5.77 0.11 
F127 118.19 1.52 0.06 0.02 -40.97 1.08 5.58 0.27 
 
Depending on the stabilizer used, differences in particle size occurred, but made no substantial 
differences for the outcomes of the encapsulation experiments (see section 3.1.3). However, 
differences in size were unexpected in some cases: 
As the Pluronics (F68/F127) and the Tween (TW21) are amphiphilic molecules, their function as 
stabilizers in the primary emulsion could have an impact on the particle size during the preparation as 
well (see Figure 3.1). PVA and PEG are both polymeric molecules, not consisting of different blocks. 
While PVA mainly stabilizes due to its partly deacetylation, PEG may only be able to act as spacer 
between molecules, as no amphiphilic parts are present in the structure. A small yet significant 
decrease (p < 0.05 in comparison to BK) of size can be observed. The most interesting result considering 
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that is the size of the PL particles. In their primary emulsion, asides from water, only desmopressin was 
present. Nevertheless, there is a significant drop in size (p < 0.05), compared to the blank particles (BK), 
where there was nothing but water in the primary emulsion. The particles of the coating approach (CT), 
which were prepared in the same way as the blank particles (BK) and later coated with desmopressin, 
had no significant size difference (p > 0.1) to the blank particles. As desmopressin is to be expected to 
sit on the surface of coated (CT) as well as on plainly encapsulated particles (PL), a measuring artifact 
by change of hydrodynamic diameter, due to desmopressin on the surface, can be ruled out. This leads 
to the assumption, that the emulsion of ethyl acetate in water is likely to be influenced even by non-
amphiphilic non-polymer molecules – in this case desmopressin. 
 
 
Figure 3.1: Sizes of PLGA nanparticles prepared with different stabilizers in the inner/primary emulsion. Stabilizer in the 
secondary emulsion was PVA. 
 
The three amphiphilic stabilizers create much smaller particles than the others. Especially Tween 21 
particles are small. Comparing those three stabilizers, what stands out is, that the two Pluronics are 
quite hydrophilic with HLB values of 29 (F-68) and 22 (F-127), while Tween 21 has a HLB value of 13.3. 
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Probably, the value of Tween 21 (13.3) is closer to the optimum HLB value of ethyl acetate, and 
therefore the emulsion droplets and the particles become smaller.  
 
3.1.2 Particle dry weights 
To calculate the loading efficiency, as drug to polymer ratio, the amount of polymer in 1 mL of particle 
dispersion was determined, as described in section 2.2.2 (Dry weight analysis).  
 
 
Figure 3.2: Dry weights of nanoparticle dispersions, measured after freeze drying and thermogravimetric analysis. (n = 3) 
 
The amount of PLGA particles that should occur in 1 mL dispersion in case of no loss, would be 2.5 mg. 
The found values indicate, that the applied method provides the particles in dimensions close to its 
input. While no strong variation from the blank (BK) can be seen for coating (CT) and plain 
encapsulation (PL) samples, all other samples exhibit a smaller amount of dry weight. In first place, this 
is contrary to expectations, as the stabilizer that was additionally put into the samples, in contrast to 
CT, BK and PL, should also have its weight. However, this could indicate, that washing the samples 
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removed the stabilizer and the PVA of the secondary emulsion quite well. A reason for the lower weight 
could be, that the nanoparticle pellets were not as dense after centrifugation with additional stabilizers 
as without, and thus more particles were lost in the washing procedure. A stronger adsorption to 
surfaces, and thus a loss during production process, could also be a reason. 
 
3.1.3 Encapsulation of desmopressin into PLGA nanoparticles 
For the encapsulation, desmopressin acetate was chosen. It is a hydrophilic, robust and synthetic 
peptide of nine amino acids length. Encapsulating the hydrophilic compound into a hydrophobic 
polymer posed a challenge and provided the opportunity to test the effects of different stabilizers on 
encapsulation. Encapsulation efficiency and loading efficiency were calculated. While encapsulation 
efficiency is especially important from an economical point of view, as it shows how much of the 
expensive drug actually goes to the produced formulation, the loading efficiency is more of therapeutic 
importance, as it relates the mass of the excipient to the mass of the drug, and thus provides 
information on dosage dimensions (see Equation 2.6 and Equation 2.7 in section 2.2.2). 
The exact values of loading and encapsulation efficiencies, determined with HPLC, can be seen in Table 
3.2. The highest loading efficiency was obtained with Pluronic F-68 as stabilizer (1.16 ±0.07 µg/mg), 
with a small difference to Pluronic F-127 (1.06 ±0.11 µg/mg). For the PEG (0.95 ±0.04 µg/mg) and the 
TW21 (0.90 ±0.05 µg/mg) approach, a higher loading efficiency than the coating approach could be 
determined, while for PVA (0.77 ±0.17 µg/mg) the result was not conclusive, due to a high standard 
deviation. The value of the PL (0.88 ±0.09 µg/mg) approach was close to the CT (0.74 ±0.01 µg/mg) 
approach that did not allow a clear statement; therefore, a statistical analysis by applying a two sample 
t-test with different variances was performed. The result of the test was that PEG, TW21, F68 and F127 
significantly differ from the CT approach (p < 0.05), while for PVA and PL this could not be found. 
Especially interesting is the fact that F68 is also significantly higher than PL, which underlines that there 
is no significant difference between PL and CT, and thus using no stabilizer results in coating the outer 
surface of the particles. 
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Figure 3.3: Loading efficiencies of desmopressin in PLGA nanoparticles in dimensions of µg per mg. The dry weights, measured 
with thermogravimetric analysis displayed in Figure 3.2, were used for calculation. T-tests revealed that the samples PEG, 
TW21, F68 and F127 each are different from the CT approach with p < 0.05. (N = 3) 
 
Table 3.2 Encapsulation and loading efficiencies of desmopressin into PLGA nanoparticles 
 CT PL PVA PEG TW21 F68 F127 
Encapsulation 
efficiency [%] 
6.66 
±0.02 
7.63 
±0.20 
6.38 
±0.34 
7.17 
±0.07 
6.66 
±0.10 
8.60 
±0.13 
8.64 
±0.22 
Loading 
efficiency 
[µg/mg] 
0.74 
±0.01 
0.88 
±0.09 
0.77 
±0.17 
0.95 
±0.04 
0.90 
±0.05 
1.16 
±0.07 
1.06 
±0.11 
 
3.1.4 Desmopressin integrity after encapsulation 
Desmopressin as a peptide is more prone to degradation than most other substances. To ensure that 
desmopressin is still intact, it was analyzed with mass spectrometry after the dissolution of the 
particles and the complete release of desmopressin. 
50 
 
The dissolved desmopressin was first separated by liquid chromatography in the LC-MS device, and 
then a total ion chromatogram was measured in positive scanning mode. Desmopressin has two 
charges, such that with a molecular weight of 1068.4269 the main peak of the ion would be at an m/z 
ratio of 535.5.[134] 
 
 
Figure 3.4: Total ion chromatogram of desmopressin determined with mass spectrometry. The peak at 535.4 (red arrow) is 
the double positively charged desmopressin. The peak at 1069.4 (green arrow) is desmopressin with only a single group 
charged. The area indicated by the blue bracket is where fragments of desmopressin should be visible if there were any. 
 
Figure 3.4 shows the total ion chromatogram of a 1 µg/mL desmopressin standard (not dissolved 
particles). The peak at 535.4 m/z (red arrow) shows the intact desmopressin, fractured desmopressin 
could not be found as explained below: 
A fractured piece of desmopressin could have two charges, and thus be lower in m/z ratio than the 
whole molecule (and the second fractured part would not appear, as it had no charge). Or there would 
be two parts with one charge each, then one would be larger than the ion at 535.4 m/z and one would 
be smaller (or both would be 535.4, which is highly unlikely). The fact, that there is no significant peak 
below 535.4 m/z (blue bracket area in Figure 3.4), shows that desmopressin has not been fractured. 
The peak at 1069.4 (green arrow) is exactly the molecular weight of desmopressin plus one proton that 
is responsible for the charge; furthermore, the double charged desmopressin has an m/z ratio of 535.2, 
if the two ionization protons are taken into account ((1068.4 + 2)/2 = 535.2). This demonstrates that 
the disulfide bond between the two cysteine residues is still intact, as otherwise the m/z ratio should 
be 1070.4 or 636.2, because of the protonation of the two sulfur groups. 
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Figure 3.5: The upper part of the image shows the liquid chromatogram, with the retention peak of desmopressin at 3.88 
minutes (purple arrow), where the total ion chromatogram (lower half of the image) was measured. Analogous to the 
standard in Figure 3.4, the red arrow points at the double charged desmopressin peak, the green arrow at the single charged 
desmopressin peak, and the blue bracket indicates the area where fragments of desmopressin should be visible, if there were 
any. 
 
Figure 3.5 shows the LC chromatogram (upper) as well as the total ion chromatogram of the mass 
spectrometer (lower) of the F68 sample. In the chromatogram, the retention of desmopressin occurred 
after roughly 3.9 minutes (see purple arrow). All other peaks are either due to the sample injection, or 
due to baseline drift; thus, they are not relevant for the analysis. The mass spectrum has therefore 
been taken from a retention time of 3.83 – 3.95 minutes. As can be seen in the lower graph, the peaks 
map perfectly to the peaks of the standard in Figure 3.4. Therefore, it can be concluded, that 
desmopressin is not affected by encapsulation or particle dissolution in any way. These findings were 
analogous to the results of all other experiments (CT, PL, PVA, F127 and TW21). The total ion 
chromatogram of the PEG approach looks different, compared to the other samples, as PEG itself 
produces very typical peaks in the mass spectrometer. If these PEG-typical peaks are ruled out, the 
chromatogram looks analogous to all others. 
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3.1.5 Coating of PLGA nanoparticles with hLF-Peptide 
A functionalization of the PLGA nanoparticles is an important next step towards the application. The 
human lactoferrin peptide is derived from the lactotransferrin protein, which is known for anti-
microbial and anti-fungal activity.[135, 136] It was already known, that the peptide is a penetration 
enhancer that can be used to mediate penetration into cells.[105] A coating of PLGA particles with hLF-
peptide could result in an increased uptake of particles into the cells or through the thin squamous 
epithelium of the deep lungs, and in this way it could result in a better bioavailability of a drug 
transported in functionalized particles. 
 
 
Figure 3.6: Concentration of hLF-peptide on PLGA nanoparticles and in the supernatant posterior to coating. Over seven days, 
the concentration of the hLF-peptide on the particle stays constant, as no release to the medium (MQ water) could be seen. 
The data point of day 0 was taken right after the coating experiment. (n = 3) 
 
Figure 3.6 shows the surface coating experiment of hLF-Peptide on PLGA nanoparticles (described in 
section 2.2.2). As can be seen, the concentrations of hLF-Peptide in the supernatant (round) and on 
the particles (squares) do not change over time. As each data point has been prepared as a single 
sample and not as one sample from which amounts were taken every day, there was no change in 
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concentration in the samples. The concentration in the vial that was left for one day, is the same as in 
the vial that was left for seven days – in case of both: particles and supernatant. This indicates, that 
the hLF-Peptide can be stably adsorbed to the surface of PLGA particles, and thus a functionalization 
is possible. 
 
3.2 Hydrophilic microparticles 
This section explains the results of the preparation of hydrophilic microparticles. Aside from the 
characterization of the prepared particles, the method is explored in more depth and the 
encapsulation of desmopressin directly into the microparticles is discussed. 
 
Particle preparation – An overview 
The preparation of particles follows a simple process, which is quite similar to the preparation of PLGA 
nanoparticles. The core difference is, that the phases are switched. While in case of PLGA nanoparticles, 
an emulsion of ethyl acetate in water is produced and by volume expansion of water the partially 
soluble solvent ethyl acetate dissolves in water leaving the PLGA to precipitate, a method with 
switched phases is more complex. Ethyl acetate in water emulsions are easy to stabilize with PVA or 
water soluble stabilizers; however, water in ethyl acetate emulsions are different, as PVA has a very 
low solubility in ethyl acetate. Therefore, a step in between, where a stable emulsion was formed prior 
to precipitation, had to be introduced. This disadvantage of an extra step, on the other hand, leaves 
the opportunity to process the emulsion before the precipitation step, without worrying about volume 
changes. During the precipitation step (see Figure 2.4), both liquids of the emulsion mix with the 
precipitation solvent; only the compound dissolved in the inner phase of the emulsion will be 
precipitated by the precipitation solvent. The choice of the three solvents that interact with each other, 
is crucial for the method. While the two solvents of the emulsion must not mix with each other, they 
both have to mix in the precipitation solvent at the same time. In most experiments conducted, 
pentane was used as outer phase of the emulsion; however, hexane and heptane both worked as well. 
Pentane was used because it evaporated quickly, and thus provided a possibility to condense 
emulsions easily during the development phase. At a later point, liquid paraffin was introduced, 
because of the better biocompatibility. Also, the emulsions in paraffin tended to be more stable than 
those in pentane, which could be due to the higher viscosity of paraffin. Besides, ethyl acetate, acetone 
and ethanol were tested as precipitation solvents; however, in both cases no homogenous particles 
could be prepared, but flocks that sedimented quickly. Also, ethanol was too polar for some of the 
stabilizers used for the emulsion. It is probable, that the partial miscibility of water and ethyl acetate 
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is the necessary characteristic for a proper particle formation; however, other partially miscible 
solvents have not been tested, as most of them are not as biocompatible as ethyl acetate. 
The preparation of the emulsion had two primary aspects: the choice of a suitable stabilizer, as well as 
a way to apply energy to form the emulsion. One of the most common ways to produce emulsions is 
a high shear homogenizer (e.g. UltraTurrax®) that blends the mixture in an emulsion. This method is 
easy and quick, but was only used for proof-of-principle experiments. Many modern pharmaceutical 
formulations have peptides or proteins as therapeutically active ingredients, which are very sensitive 
to the application of energy. Forming an emulsion without directly applying energy to the compounds, 
was desired. Membrane emulsification provides a scalable method that allows to apply energy, while 
ensuring that this energy is not applied to the active ingredient. However, the size of the emulsion 
droplets correlates with the pore diameter of the membrane used, and thus causes a higher friction 
between solvent and membrane. Since polymer solutions had to be turned into emulsions, the 
viscosity of the polymer in solution added a large factor to the friction between solvent and membrane. 
For dextran, as an extremely water soluble polymer, small pores posed not much of a problem, in 
comparison to gelatin or even glucomannan, which were unable to pass the membrane in some cases. 
Applying higher gas pressures would rather result in a separation of polymer and water on the 
membrane surface. Therefore, membrane emulsification experiments were only conducted with 
dextran and chitosan.  
The choice of the correct stabilizer was difficult. For the first experiments, Brij O2 (2.5%) was used; 
however, despite being a very lipophilic stabilizer (HLB: 5), the dissolution in alkanes did not always 
work well. For this reason, the more lipophilic component Span 85 (HLB: 1.8) was chosen. Preparing 
the emulsion worked well, but for the precipitation, and especially for further washing steps with 
ethanol, the stabilizer was too hydrophobic, and thus it did not mix with the washing solvent and 
stayed in the sample. The stabilizers were then changed to a concentration of 0.25% of Tween 85 and 
Span 80 each, following an example in the manual of the membrane emulsification device. Tween 85 
with an HLB of 11 could not dissolve in the alkane; however, upon adding Span 80 (HLB 4.3), both 
stabilizers dissolved well. Also, the mixture of these two stabilizers (HLB 7.65) dissolved in ethyl acetate 
and could be washed with more polar solvents like ethanol. Since droplet size mainly depends on the 
pore size of the membrane, as described in the “membrane emulsification” part of section 2.2.1, 
experiments with different HLB values or stabilizers were not of higher priority. 
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Figure 3.7: The image shows dried dextran particles. Many dextran particles are fractured or broken down to debris. 
 
Among the organic solvents, ethanol is probably one of the most biocompatible; however, particles 
cannot be administered in pure ethanol, neither on pulmonary route nor on any other, such that the 
ethanol had to be removed as well. The first approach taken for this problem was the evaporation of 
ethanol. Since the raising concentration of particles during the evaporation caused aggregation of the 
particles, as a step to prevent aggregation the sample was placed in an ultrasound bath. The 
continuous ultrasound did not only prevent the particles from aggregation, it also fractured many of 
them, resulting in particle debris (see Figure 3.7). As a result of this, freeze drying was chosen as a 
possible approach to overcome that problem. Once frozen, the particles would not move anymore, 
and the solvent could be removed. Since ethanol has a very low freezing point (-114.5 °C), this was 
impracticable in our laboratory. Therefore, after the washing step with ethanol, the solvent was 
changed to acetonitrile, which has a freezing point around -45 °C. Except for the experiments with 
Pluronic F-127, there was no other reason to use acetonitrile than this, and for any pharmaceutically 
relevant application in production acetonitrile should be left out, as it is more toxic than ethanol. 
 
3.2.1 Preparation of uniform sized particles 
Particles are prepared by precipitation from an emulsion droplet; therefore, it is assumed that the 
particle size correlates with the size of the emulsion droplets. Emulsions prepared by membrane 
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emulsification usually have a wider size distribution, but multiple membrane cycles can homogenize 
the droplet size distribution very well, as shown by [137] for oil in water emulsions. 
In the experiment to prepare uniform sized particles (Experiment # 6, see section 2.2.3), in the first 
cycle an aqueous chitosan solution was pressed through a glass membrane. The result of the first cycle 
was larger droplets that sedimented quickly. After sedimentation, the droplets were taken into a 
second cycle, in which they passed the membrane again. This was repeated 2 more times. (see Figure 
3.8) 
 
 
Figure 3.8: Homogenization of the emulsion droplets. The emulsion is prepared (A), after sedimentation the larger droplets 
are collected and emulsified again (B). The latter step is executed three times. 
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As a result of further membrane cycles, the emulsion turned more opaque with each step. An SEM 
image of the precipitated particles suggests, that there is a distribution of smaller particles and one of 
larger particles (see Figure 3.9). To determine the actual size distribution, the dispersion was analyzed 
with a Retsch Horiba LA-950. The result graph (Figure 3.10) plots particle diameters versus the 
volume % of the particle’s corresponding diameter. The peaks shown are rather broad and unexpected, 
when comparing to what can be seen in Figure 3.9. However, the result yields some interesting 
numbers. The cutoff in the image (purple line) was chosen at 1 µm, indicating that 31.35% of the total 
volume are of 1 µm size or lower. As volume scales by third power, ten times larger particles have 1000 
times more volume. Considering this fact, it becomes clear that there must be more small particles 
than large particles. To visualize this, particle sizes of 361 particles in three different images were 
measured by hand. The result in Figure 3.11 shows that most particles are below 1 µm, peaking in sizes 
between 0.6 and 0.69 µm.  
 
 
Figure 3.9: Chitosan particles prepared with membrane emulsification, multiple membrane cycles and precipitation. Among 
many small particles (orange arrows) few larger particles (green arrow) can be seen. 
 
58 
 
 
Figure 3.10: Particle size distribution by volume, measured with a Retsch Horiba LA-950. The X-axis shows the size of the 
particles, while the left Y-axis (referring to the lower blue line) shows the figures of volume-% in particles of the corresponding 
size. The right Y-axis refers to upper blue line and shows the cumulative volume-% of particles. The purple line at 1.0 µm shows 
the cutoff, at which the three values written below the graph are indicated: 1 µm particles make 1.49% of the total volume, 
while 31.35% of the total volume are of 1 µm size or lower. Refractive indices for calculation were used from starch and nylon, 
as they were closest to the values. The sample was measured in ethyl acetate. 
 
These results indicate, that it is possible to produce large amounts of Chitosan nanoparticles with the 
presented method. The multiple membrane cycles created a large fraction of smaller particles. Maybe, 
more membrane cycles would even pronounce this effect. Also, the size is quite surprising, as 0.6 – 0.7 
µm is only 1.2 to 1.4 times the size of the pore size of the membrane used (0.5 µm). The peak in the 
volume distribution result in Figure 3.10 has its maximum between 0.3 and 0.4 µm, in contrast to 0.6 
µm in Figure 3.11. As the refractive index of Chitosan is only estimated with similar components, the 
laser diffraction method probably underestimates the actual size of the particles. A loss of smaller 
particles during washing is rather unlikely, as the PTFE filter membrane that was used had a pore size 
of 0.1 µm which would hold back particles of sizes around 0.3 – 0.4 µm without a larger loss. 
Nevertheless, this concludes to the suggestions to use a membrane with slightly larger pore size for 
future experiments, as the particle distribution should then move rather in the direction of 1 µm sized 
particles. 
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Figure 3.11: Particles size distribution by numbers. For measuring all values, 361 particles in three different images were 
counted and measured. Only particles of the size between 0.3 µm and 1.69 µm were considered, as larger particles occurred 
only very sparsely. The size distribution peaks between 0.6 and 0.69 µm. 
 
Figure 3.12: Long-term stability image of ME Chitosan particles. The image was taken about 11 months after the image of 
Figure 3.9. 
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Figure 3.12 shows the same sample as in Figure 3.9, but about 11 months later. Upon a close look, no 
differences between the particles can be seen. Considering the fact, that the particles were stored at 
room temperature and sealed under air atmosphere, the particles seem to be stable. This counts not 
only for the big, but also for the small particles, where the surface is larger in comparison to their 
volume. 
 
3.2.2 The use of Pluronic F-127 as porosity agent 
In the first place, Pluronic F-127 was used in the aqueous phase of the emulsion to have a stabilizer 
that helps to decrease the friction during the emulsification process inside the pores of the membrane. 
The significant reason for higher friction, however, was rather an obstruction of the membrane pores 
by the polymer than the friction, as the Pluronic did not solve this problem. But it was found in 
preliminary experiments, that particles that contained Pluronic F-127 had unexpected structures (see 
Figure 3.13). Both particles shown in Figure 3.13 seem to have similar inverse structures. The only 
difference between them is the solvent that was used for purification. Water-ethanol mixtures dissolve 
Pluronic F-127 well; however, pure ethanol does not dissolve, but probably soften and swell it. The 
dextran particle on the left image (A) was washed with ethanol only; a porous structure cannot be 
seen, but the popping out parts are probably Pluronic F-127. The dextran particle on the right (B) was 
washed with acetonitrile which dissolves Pluronic F-127 well. From this it was concluded that Pluronic 
F-127 can be washed out from Pluronic/Dextran particles, in order to obtain porous dextran particles.  
 
 
Figure 3.13: Dextran particles prepared with Pluronic F-127. While the particle on the left side (A) has been washed with 
ethanol, a substance that softens, but not fully dissolves Pluronic F-127, the particle on the right side (B) was washed with 
acetonitrile which dissolves Pluronic F-127 easily. 
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To confirm this, a set of experiments was conducted with different concentrations of Pluronic F-127. 
The experiments are described as Experiments # 1, # 2, # 3 and # 4 in section 2.2.3). While experiment 
# 1 was a negative control, in experiments # 2, # 3 and # 4 Pluronic F-127 was added in concentrations 
of 0.1, 1.25 and 5 wt% respectively. 
 
 
Figure 3.14: Dextran particles prepared without Pluronic F-127 (A) and with 0.1 wt% Pluronic F-127 (B). Red arrows mark 
preparation-typical dents (deformations) of particles. Yellow arrows mark porous like structures and blue arrows mark unusual 
deformations. 
 
 
Figure 3.15: Dextran particles prepared with 1.25 wt% Pluronic F-127 (C) and with 5 wt% Pluronic F-127 (D). Red arrows mark 
preparation-typical dents (deformations) of particles. Yellow arrows mark porous like structures and blue arrows mark unusual 
deformations. 
 
The image of particles prepared without Pluronic F-127 (Figure 3.14, Image A) shows particles that are 
of round shape. Some of them have dents (red arrows). These dents are typical for dextran particles 
prepared with this method, they can be observed in all samples. Looking at image B, where 0.1% 
Pluronic F-127 was used, we additionally recognize slightly deformed particles (blue arrows) and 
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porous structures (yellow arrows). The image of particles with 1.25% Pluronic F-127 (Figure 3.15, Image 
C) shows much stronger deformations than on image B; however, there are also more porous 
structures that can be seen. Comparing that with Image D, we even have more deformations there, 
but not more porous structures. It appears, that the images with Pluronic F-127 have porous structures 
in comparison to the one without, but the degree if porosity does not seem to change much. On the 
other hand, the degree of deformation seems to increase with an increasing amount of Pluronic F-127. 
At first glance this does not propagate the results of Figure 3.13; however, during the experiments it 
could be observed that aqueous Pluronic F-127 solution and the aqueous dextran solution tend to 
separate into two different phases. While the experiments of Figure 3.13 were prepared as single 
experiments in relatively short time, the experiments of Figure 3.14 and Figure 3.15 were prepared 
simultaneously, generating longer periods where the emulsified sample batches idled for further 
processing. Therefore, there is a high possibility that a phase separation took place in the droplets of 
the emulsion. This would not only explain why there are only few porous structures, but also why there 
are increasing amounts of deformations with raising concentrations of Pluronic F-127. Then, during 
the washing step with acetonitrile, whole parts of the dextran/Pluronic particles were dissolved and 
washed away. Looking at Figure 3.13 B again and considering the size of the holes that are between 50 
and 150 nm, it becomes clear that holes of this size could not develop if dextran solution and Pluronic 
solution were well-mixed. 
Unfortunately, the experiments conducted cannot prove the hypothesis derived from Figure 3.13, so 
that an additional experiment was necessary to confirm the assumptions. Since time seemed to be a 
factor, the emulsion was not prepared with membrane emulsification but with a high shear 
homogenizer. In the process, 2 mL of a 10 wt% dextran and 2.5 wt% PLuronic F-127 solution were 
emulsified in 18 mL of pentane with stabilizers as before. The particles after precipitation were washed 
with ethyl acetate and then transported and kept in acetonitrile to dissolve the Pluronic F-127. For 
imaging, the particles were dried on an SEM wafer and then imaged. 
The particles of the conducted experiment have a clearly porous structure, as it had been expected 
according to the assumptions (see Figure 3.16). Indeed, it is possible to prepare porous particles by 
mixing dextran and Pluronic F-127, and probably the degree of porosity can be adjusted by the ratio 
of dextran and Pluronic F-127, but this also shows that there are two different aqueous phases (dextran 
and Pluronic F-127) and that both tend to separate by time. A better stabilization of the water in water 
emulsion would be beneficial for future work. 
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Figure 3.16: SEM-image of particles prepared with Pluronic F-127 as porosity agent. The emulsion was prepared with a high 
shear homogenizer to achieve a precipitation before phase separation of dextran and pluronic. The porous structure can be 
seen on many particles. 
 
3.2.3 Preparing particles with different polymers 
To further demonstrate the flexibility of the presented preparation method, particles were prepared 
from various biocompatible and biodegradable polymers. Since most of the polymers had a higher 
viscosity in solution than dextran and chitosan, the emulsions were not prepared by membrane 
emulsification but with a high shear homogenizer (section 2.2.3, Table 2.3, Experiments # 7 till # 12). 
These experiments were not adjusted for homogeneous particle distributions, but they demonstrate 
the feasibility of the method for many different polymers very well. 
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Figure 3.17: Comparison of particles of different polymers, prepared with either “membrane emulsification precipitation“ (ME) 
or with “high shear homogenizer emulsification precipitation“ (UT). The two membrane emulsification images have four and 
one membrane cycle for chitosan and dextran respectively. All images show particles with the same magnification. Scale bar 
= 1 µm, (GCM = glucomannan). The ME Chitosan image has previously been discussed in section 3.2.1. 
 
The comparison image (Figure 3.17) shows particles prepared from different biocompatible, 
biodegradable and thus pharmaceutically relevant polymers. The only exception to this is lignin which 
has currently no pharmaceutical relevance, but it is suggested that the prerequisites for that are 
given.[138] All images in the figures are taken with the same magnification, such that a comparison of 
the different particles is possible. While particles of UT Chitosan, UT Dextran and ME Dextran are 
similar in size, particles of UT Gelatine, UT Alginat and UT Lignin are a bit smaller. The particles of UT 
GCM and ME Chitosan are much smaller in comparison to the others. 
 
 
Figure 3.18: The image (A) shows dextran particles prepared with the high shear homogenizer precipitation method. Image 
(B) is the long-term stability image of the same particles about 11 months later. (Experiment # 7, Table 2.3) 
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Dextran particles prepared with the high shear homogenizer method (Figure 3.18) (A) show a relatively 
wide size distribution. While there are a lot of very small particles well below 1 µm in size, there are 
also many larger particles. As many of the larger particles are collapsed or just shells (red arrows), it is 
suggested that many, or possibly all, larger particles are hollow to some extent. It also occurs that some 
of the larger particles merge into each other and into the larger particles. 
The long-term stability image (B) shows stable particles; however, the surface of those particles seems 
a little bit smoother than in (A). Probably, the surface of the dextran particles dissolved slightly, due to 
the hydrophilicity of the polymer in air humidity. 
 
 
Figure 3.19: Dextran particles prepared with membrane emulsification precipitation method (A). Long-term stability image 
(B) taken after about 11 months. (Experiment # 1 Table 2.2) 
 
In Figure 3.19 (A), dextran particles prepared with membrane emulsification are shown. The size 
distribution is very wide, similar to the Figure 3.18. Also, the smaller particles are sticking to each other. 
Hollow particles cannot be seen on this image, but the large dent (red arrow) indicates that some of 
them are hollow as well. On other membrane emulsification/dextran images in this thesis, hollow 
dextran particles have been shown (e.g. Figure 3.7), such that we can assume that there is no 
difference in this case to the particles prepared with the high shear homogenizer. What appears to be 
different, is the amount of small particles which merge into each other. While in Figure 3.18 the smaller 
particles are still well distinguishable, here, they often seem to have merged into a single mass without 
form.  
The long-term stability image (B) shows, just as in Figure 3.18, stable particles with a slightly smoother 
surface. Also, smaller particles seem to be more melted into each other than on image (A). 
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Figure 3.20: Chitosan particles prepared with high shear homogenizer precipitation method (A). Long-term stability image (B) 
taken after about 11 months. (Experiment # 8, Table 2.3) 
 
The chitosan particles in Figure 3.20 (A) seem to have a more narrow size distribution, compared to 
the dextran particles. Especially, there are only few very small particles in comparison to the batches 
of dextran particles. Also, all larger particles seem to have collapsed, because they are hollow (red 
arrows). Some of the particles merge with the background; however, barely any particles can be seen 
that merge with each other, which is also a difference to the dextran particles. 
The long-term stability image shows no differences to image (A), therefore it can be concluded, that 
the storage did not affect the chitosan particles. This is also consistent with the finding of Figure 3.12. 
 
 
Figure 3.21: Alginate particles prepared with the high shear homogenizer precipitation method (A). Long-term stability image 
(B) taken after about 11 months. (Experiment # 9, Table 2.3) 
 
The alginate particles shown in Figure 3.21 (A) have a relatively wide size distribution. While large 
particles seem to be hollow and collapsed (red arrows), also some of the smaller particles seem to 
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have hollow characteristics (blue arrows). What stands out is the fact that many particles seem to have 
merged with others or with non-particulate mass in the background. Most alginate particles in 
literature are crosslinked with divalent ions such as Ca2+ or Mg2+. Obviously, this is not a prerequisite 
for preparing particles from alginate, but maybe using a crosslinker could reduce the amount of 
merging particles. The long-term stability image (B) shows no differences to image (A). 
 
 
Figure 3.22: Particles prepared from glucomannan with the high shear homogenizer precipitation method (A). Long-term 
stability image (B) taken after about 11 months. (Experiment # 10 Table 2.3) 
 
The particles in Figure 3.22 (A) have a very homogeneous size distribution and are relatively small 
compared to the dextran, chitosan (High shear homogenizer approach) and alginate particles. While 
the few larger particles seem to be hollow (red arrows), there are some smaller particles with dents 
(blue arrows) which could indicate that at least some of the smaller particles are hollow as well. 
Merging particles can be seen, but they are relatively rare, compared to the amount of all particles. A 
reason for the great number of small particles could be, that prepared samples of the glucomannan 
approaches only yielded a tiny amount that could be analyzed. It is highly likely, that there once were 
many larger particles that got lost during preparation, as the final sample contained almost no mass. 
Possibly, the sticky nature of the polymer resulted in adsorption to surfaces during the process. The 
smaller particles that did not sediment, would not touch the surfaces of their storage vials, and thus 
would not attach to it. 
On the long-term stability image Figure 3.22 (B), only a very small number of particles can be seen at 
the border to the bulk material. The reason could either be, that the particles are unstable and 
degraded over time, or as mentioned above, that there was only a tiny amount of the sample and in 
the measured preparation no particles could be found. 
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Figure 3.23: Gelatin particles prepared with high shear homogenizer precipitation method (A). Long-term stability image (B) 
taken after about 11 months. (Experiment # 11, Table 2.3) 
 
The gelatin particles in Figure 3.23 (A) look very different, as the surface of the particles appears much 
smoother compared to the polysugar particles shown before; however, they exhibit the same 
characteristics: larger particles are hollow and collapsed. The thin nature of the particles walls is well 
visible because of the high contrast. Also, some smaller particles show dents which could indicate that 
they are hollow as well. The size distribution is wide, as in case of most other high shear homogenizer 
experiments. 
The long-term stability particles in Image (B) do not look different from those in (A), which is surprising, 
as gelatin as a protein is prone to degradation of many microorganisms. The sample was kept sealed, 
yet not sterile. The dry conditions seem to be sufficient to prevent microbial settling. 
 
 
Figure 3.24: Lignin particles prepared with high shear homogenizer precipitation method (A). Long-term stability image (B) 
taken after about 11 months. (Experiment # 12, Table 2.3) 
69 
 
The lignin particles in Figure 3.24 (A) look very different from all others. This has multiple reasons: the 
main one is probably that NaOH was used in Experiment # 12 to dissolve the lignin in water. Since the 
NaOH could not be removed in the process, it is still a part of the particles shown on the image. 
Crystallization of smaller fragments of NaOH could be the reason for some sharper edges of the 
particulate structures or for the etched surfaces. In general, it is easy to find particle-like structures 
but hard to find actual particles; however, some are there (yellow arrow). Also, some of the remaining 
particles seem to have hollow structures (red arrows), but in this case it is unclear if it is for the same 
reason as in all other experiments, or if it is due to the nature of the lignin or the NaOH. Furthermore, 
it should be considered that the particles were prepared in paraffin instead of pentane. This did not 
make a difference during preparation, but could have had an influence on the result. The long-term 
stability image (B) shows no differences to image (A). 
 
3.2.4 Encapsulation of desmopressin into dextran microparticles 
As desmopressin is a hydrophilic substance, it can be encapsulated into dextran directly. The prepared 
particles, as described in section 2.2.3, were dissolved in water (5 mg of particles in 1 mL of MQ water) 
and then analyzed with HPLC. As some amounts get lost during the membrane emulsification due to 
its dead volume, only relative values of encapsulated desmopressin are considerable: Assuming that 1 
mg of desmopressin was distributed in 300 mg dextran plus 0.5 mg Pluronic F-68, a maximum 
concentration of 3.32 µg desmopressin in 1 mg particulate substance is possible. From three produced 
batches, that all were measured three times in HPLC, an average amount of 2.46 ± 0.33 µg 
desmopressin per 1 mg could be detected. This means, that the concentration of desmopressin in the 
particles is 74% of the maximum possible amount defined by the experimental setting. It shows, that 
desmopressin and dextran are well miscible and that desmopressin does not much tend to mix with 
ethyl acetate.  
On the other hand, the difference between the three batches is quite high, as it can be seen in Figure 
3.25. This can also be seen, when considering that the standard deviation of the mean value is more 
than 10%. Since all three samples were prepared in a row, and thus batch 1 was at rest while batches 
2 and 3 were prepared, and likewise batch 2 was at rest while batch 3 was prepared. The linear raise 
of encapsulated desmopressin by batch number could be an indication of release of desmopressin over 
time. However, since this would be a release into pentane, the argument is not very solid. There might 
as well be an accumulation at the droplet interphase and a washing off during precipitation and 
afterwards. 
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Figure 3.25: Amounts of desmopressin per milligram particle powder. The dextran particles were prepared with membrane 
emulsification. 
 
3.3 Encapsulating PLGA nanoparticles into dextran microparticles 
The logical conclusion to the findings of a nanoparticle system that can be functionalized in section 3.1 
and a water-soluble microparticulate system in section 3.2, would be a combination of both. To see, 
whether it is possible to encapsulate PLGA nanoparticles into the dextran microparticles and to have 
an optical readout, fluoresceinamin-PLGA (covalently linked) was used to prepare nanoparticles. The 
nanoparticles were prepared analogously to normal PLGA nanoparticles. After centrifugation and 
washing of the pellet, these fluorescent nanoparticles were then mixed with the dextran solution and 
processed to become dextran particles, by membrane emulsification. Since the PLGA particles had 
sizes too large for 0.5 µm pore membrane, the dextran particles were prepared by using a membrane 
with a pore size of 2 µm. The dextran particles were not dried, but their solvent was changed to ethanol 
to avoid the further dissolution of PLGA nanoparticles (in ethyl acetate) or the dissolution of dextran 
particle under humid air atmosphere. The confocal images were taken directly in ethanol, as described 
in section 2.2.4. 
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Figure 3.26: Image of dextran particles prepared with FA-PLGA nanoparticles. FA-PLGA nanoparticles are fluorescing in green 
color. The upper left image (A) is a fluorescence image, the upper right (B) a non-fluorescence light image, the lower left (C) 
an overlay of the two upper images. The scale bars are 2 µm. The red arrow shows a dextran particle that has been loaded 
with nanoparticles, while the blue one shows a particle that remained unloaded. 
The resulting particles were investigated with confocal microscopy, as it can be seen in Figure 3.26. 
The fluorescing spots in image A can be identified as particles in image B (red arrows). Therefore, it 
can be concluded that FA-PLGA nanoparticles are incorporated into dextran microspheres. However, 
there are also particles that can be identified as such in images B and C, but no fluorescence can be 
observed in image A and C (blue arrows). Therefore, it can be concluded that not all particles are loaded 
with the nanoparticles and some plain dextran particles remain. 
Aside from particles of 1-2 µm size, also larger particles could be found. An example of one of these 
particles can be seen in Figure 3.27. Many of these particles also contained FA-PLGA nanoparticles. 
The image shows a large dextran particle of roughly 50 µm size. There is a clearly visible core of the 
particle (purple arrow) that fluorescents brightly. Around it, there is a light absorbing and thus black 
appearing shell with few fluorescent spots (yellow arrow). On the surface of this layer, there is another, 
very thin layer of fluorescent material. The inner core is probably mainly a bulk of FA-PLGA 
nanoparticles. The shell around the core is supposedly dextran that precipitated during the 
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manufacturing process. There are still some FA-PLGA nanoparticles present; however, much less than 
in the core.  
 
 
Figure 3.27: Confocal image of a large dextran particle filled with fluorescent PLGA nanoparticles (green fluorescing). 
 
While the core contains most fluorescent particles, the shell has an outer and an inner layer, where 
there are more fluorescent spots in the inner than in the outer layer. The ethanol, in which the particles 
are dispersed during imaging, does not dissolve any material involved and keeps air humidity from the 
sample, such that no dissolutions can occur during the measuring. A release of FA-PLGA nanoparticles 
is unlikely, as dextran is bulk material and should immobilize large objects such as the nanoparticles, 
also there is no strong affection between FA-PLGA and ethanol. An explanation of the precipitation 
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process will be given in section 3.4. It is likely, that FA-PLGA nanoparticles moved to the core during 
the precipitation process. In the inner layer of the shell, the dextran is probably less dense, and 
therefore more nanoparticles can be found in this area. The fluorescent layer on the surface of the 
particle consists most likely of free FA-PLGA nanoparticles from other dextran particles that were 
destroyed during the washing process on the filter membrane.  
On the other hand, looking at the core rises the interesting question, why there is a core structure at 
all. In SEM images before, many larger particles were hollow on the inside and had holes to the surface. 
This can be excluded for this particle: If the particle would be hollow, then ethyl acetate would have 
entered the particle during the precipitation process and dissolved the FA-PLGA nanoparticles inside. 
The dissolved FA-PLGA polymer would probably have been washed out, and the little remaining 
polymer would be stuck to the inner surface rather than existing as bulk in the middle of the particle. 
On the other hand, we have to consider that FA-PLGA is hydrophobic, compared to the dextran shell. 
A self-assembly of hydrophobic particles in the center of hydrophilic particles is possible. A detailed 
attempted explanation for this phenomenon is provided in the next section. 
 
3.4 Explanation for the core shell structure of hydrophilic particles 
On most SEM images it can be seen, that many particles, regardless of the polymer used, have dents, 
and many particles, especially the larger ones, are hollow. A possible explanation of this effect needs 
to focus on the moment of precipitation. When the emulsion (Figure 3.28 (A)) is injected into the ethyl 
acetate, the alkane outer phase of the emulsion mixes with ethyl acetate (B), and thus the 
concentration of ethyl acetate around the droplet raises. Since ethyl acetate and water are only 
partially soluble solvents, it is to assume, that upon the first contact of ethyl acetate molecules with 
the water droplet, there is no mixing between both phases. As the alkane further mixes into the ethyl 
acetate, the concentration of ethyl acetate around the water droplet raises. At some point, the 
concentration of ethyl acetate around the water droplet is high enough to allow the mixing of water 
into ethyl acetate, so the droplet begins to precipitate (C). 
At this point, water diffuses out into the ethyl acetate, as well as ethyl acetate moves on into the water. 
The concentration of ethyl acetate in the water results in a precipitation of polymer in the aqueous 
phase. Since the polymer and the ethyl acetate do not mix at all, it is to assume that the outer rim of 
the particle holds back the incoming ethyl acetate on its surface; however, water constantly diffuses 
out from that surface into the ethyl acetate. If that assumption is correct, then the surface of the 
particle and its interior could exhibit different patterns, as the outer rim is precipitated by the invasion 
of ethyl acetate, while the inner part is rather dried out by loss of water. Figure 3.29 shows the breaking 
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edge of a dextran particle. The red arrows indicate the surface of the particle, where a very dense 
pattern can be seen. The blue arrow points to the inner part of the particle that has a clearly different 
pattern than the surface. Air humidity, and therefore surface dissolution as a reason for different 
patterns of the particle, can be ruled out, since the air humidity would have affected the breaking edge 
as well. The bubbles could be remains of water or of gas that were entrapped during the precipitation 
process and formed their bubble shape during the lyophilisation, because of the strong negative 
pressure. During SE microscopy, focussing the scanning beam on a part of the surface that has bubbles 
underneath, can result in inflation of the bubbles. This may be a reaction of possible gas expanding 
inside. 
 
 
Figure 3.28: General steps of the precipitation process. Aqueous emulsion droplet surrounded by alkane (A), alkane mixing 
with ethyl acetate after injection (B), start of the precipitation process at the outer rim of the droplet once enough ethyl 
acetate is present (C), diffusion of water from the inner part of the droplet to the outer ‘dried’ part (D). 
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Figure 3.29: Breaking edge of a dextran particle. Outer rim of the particle exhibiting a denser pattern (red arrows) than the 
inner part with bubble holes (blue arrow). 
 
It is likely to assume, that the deserting water in the outer part of the particle results in a flux of the 
water from the inside to the outside, especially since many of the hydrophilic polymers are quite 
hygroscopic. This flux from the inside to the outside (Figure 3.28 (D)) might even drag some of the 
polymer from the inner of the particle along to the outer part. An indication for that is the dense 
structure at the surface shown in Figure 3.29, as the polymer would concentrate here. This would also 
lead to a negative pressure in the center of the particle (Figure 3.30 (E)). Since it can be assumed, that 
the particles are still not very hard in this state, the formation of a dent is a probable result of negative 
pressure compensation. If, like assumed before, the water flux from the inside to the outside drags 
most of the polymer along, a break of the particle surface in the moment of dent formation seems 
possible. The result would be ethyl acetate flowing into the particle and pursuing its precipitation 
process from two sides (F). The extent to which these things occur, seems to vary for different polymers. 
While dextran particles exhibit holes and dents quite often, chitosan particles, especially the smaller 
ones, do not seem to have any. Larger chitosan particles also rather appear collapsed than with holes. 
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The velocity of the water flux from the inside to the outside could vary with the hydrophilicity of the 
material; however, this would have to be investigated in further experiments. 
 
 
Figure 3.30: Steps of the precipitation process, that presumably result in the formation of dents and hollow structures (E,F) or 
core shell structures in case of loaded PLGA nanoparticles (G,H).  
 
The core shell structure of the FA-PLGA nanoparticle loaded dextran microparticles could result from 
this matter as well. Considering, that the hydrophilic dextran assembles in the shell of the particle 
(Figure 3.30 (G)) and water further flows from the inside to the outside, a movement of rather 
hydrophobic PLGA particles to the inside and founding a mainly hydrophobic domain seems rational. 
This would also counter the emerging negative pressure in the center of the particle. 
77 
 
4 Conclusion 
4.1 Hydrophobic nanoparticles 
The results of the preparation of PLGA nanoparticles in section 3.1 showed, that particles could be 
loaded with a peptide drug, and that the surface of the particles could be functionalized with hLF-
peptide. This has not yet been shown for the chosen set (PLGA, desmopressin and hLF-peptide), but 
the preparation of PLGA nanoparticles in general, and the incorporation of a peptide into PLGA, is a 
common method in the field of pharmaceutical technology [18, 32], and it was thus a good starting point. 
The results of the particle preparation suggested, that the particle size could be reduced with the right 
choice of stabilizer in the inner emulsion (Tween 21 strongly reduced particle size); for a better loading 
efficiency, the most hydrophilic stabilizer Pluronic F-68 showed the best result. Pluronic F-127, being 
less hydrophilic than Pluronic F-68, had the second best result. This indicates, that there could be a 
connection between loading efficiency and hydrophilicity of the stabilizer for the encapsulation of 
desmopressin; however, the data produced in this thesis are not sufficient to serve as full evidence. 
The loading efficiency approach with Pluronic F-68 is significantly higher (p < 0.05) than the coating 
approach (CT), and also significantly higher than the approach without stabilizers (PL). A significant 
difference between CT and PL could not be found. This suggests, that the drug can only be incorporated 
into the particle if a stabilizer is present. The theory of the double emulsion technique says that the 
primary emulsion results in small bubbles inside the nanoparticles, in which the drug can be contained. 
If there is no significant difference between the PL and the CT approach, and thus the double emulsion 
approach encapsulates as much as a surface coating, it is questionable whether the double emulsion 
actually produces the proposed structure of bubbles inside nanoparticles. 
Tween 21 is by far the most hydrophobic stabilizer and produced by far the smallest particles (HLB 13.3 
versus 28 and 22 for the Pluronics). This indicates, that there could be a connection between the size 
of the particles and the hydrophobicity of the stabilizer, but also the different molecular weights of the 
stabilizers might have an impact. 
As Pluronic F-68 resulted in the best loading efficiency and Tween 21 in the smallest particles, a 
combination of both seemed to be a reasonable choice to optimize the system; however, if the HLB 
values of the stabilizers are responsible for the changes in loading efficiency and size, what is suggested 
by the data, this approach would not work. Upon mixing stabilizers, HLB values would turn average 
and none of the two effects would occur. In this case, we would only have the choice between smaller 
particles and higher loading efficiency.  
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Regarding the results from a plainly therapeutic point of view, we could reach a concentration of 1.16 
µg desmopressin per mg PLGA, which matches the ratio of common medicinal products on the market. 
Oral formulations usually have doses of 100 or 200 µg per tablet, while the average weight of a tablet 
is around 200 mg. (Desmopressin Teva®; TEVA Pharmaceutical Industries Ltd.; Petach Tikwa, Israel). 
Therefore, we can conclude that our particles should meet the therapeutic window in an application, 
and can compete with this formulation with respect to drug loading. 
Considering the efficiency of the whole process, there is a major drawback due to comparably low 
encapsulation efficiencies. Even though the encapsulation efficiency rises by about 30% due to the use 
of Pluronic F-68, less than 10% of total desmopressin are actually encapsulated into the particles. The 
rest of the peptide is removed with the supernatant. From a commercial point of view, the 
encapsulation would probably not be reasonable. 
The system would work better for hydrophobic drugs that mix well with the organic phase, and thus 
PLGA;[139] however, for targeting reasons and protection of the drug, the encapsulation into a carrier 
system is necessary. If then the microparticulate carrier system of higher order is hydrophilic, the 
nanoparticulate system to be filled into the hydrophilic microparticles has to be hydrophobic.  
In the case of a hydrophilic drug, it can directly be encapsulated into the hydrophilic carrier system (as 
described in section 3.2.4). For topical applications without a strongly degrading environment, such as 
the skin, the direct encapsulation into the hydrophilic particles is suitable and means a simplification. 
For applications where targeting, protection or continuous release is relevant, additional measures like 
a hydrophobic nanoparticulate carrier system have to be taken.  
 
4.2 Hydrophilic microparticles 
The method for preparing microparticles out of hydrophilic polymers, was created as a modification of 
the Emulsion Solvent Diffusion method, which was used to prepare hydrophobic nanoparticles. As a 
water in ethyl acetate emulsion is difficult to prepare - there is a lack of suitable stabilizers - an 
additional step of an emulsion in an alkane was introduced. This led to a method, with which particles 
of various different polymers (dextran, chitosan, alginate, lignin, glucomannan and gelatin) could be 
prepared. The particle size could be adjusted by the droplet size of the emulsion. Thus, the essential 
problem of the method is to prepare homogeneous emulsions of a certain droplet size. The mixture of 
two non-miscible solvents that mix with each other when introduced into a third solvent, is a new 
technique that has not yet been used to prepare particles in the field of pharmaceutical sciences. The 
question of toxicity is essential to pharmaceutical applications; therefore, the use of more 
biocompatible materials is desirable. If components can be replaced or do not depend on their 
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chemical properties: The polymers can be replaced as long as they stay soluble in water and insoluble 
in pentane and ethyl acetate. In that way, the system is very flexible with regard to the encapsulation 
of APIs with different properties. 
In case of the solvents, an exchange of ethyl acetate and pentane would be desirable. While for 
pentane the much less problematic liquid paraffin has already shown its potential in this thesis, a good 
replacement for ethyl acetate is still missing. Unfortunately, ethanol did not work out, which might be 
the case because it is fully miscible with water and not partially miscible like ethyl acetate. The need 
for full miscibility with pentane/paraffin and dissolution of the polymer further complicates the 
exchange. 
The encapsulation of hydrophilic components into the particles is easy, as they just have to be mixed 
with the polymer before the emulsion step, whereas hydrophobic components cannot be 
encapsulated directly; however, many of the therapeutic agents used today are not only hydrophilic 
or hydrophobic. If encapsulating an amphiphilic component, it should be considered that the 
component could easily arrange itself at the interface between oil and water. This could lead to 
denaturation in the case of proteins and peptides. This thesis did not address this issue, as the model 
drug (desmopressin) was very hydrophilic.  
The chemical properties of dextran and Pluronic F-127 led to the possibility of preparing an emulsion 
with two different aqueous phases. The simultaneous precipitation led to the preparation of porous 
dextran particles, when the Pluronic F-127 was washed out by acetonitrile. This effect and the 
prepared method allow to change the aerodynamic diameter of the prepared particles. As the 
aerodynamic diameter is important for a pulmonary delivery, this could further help to adjust a 
pulmonary formulation in a later step. 
 
4.3 Conclusion on the aim of this thesis 
Within this thesis, it was possible to set up a method of preparation that exhibits many of the desired 
characteristics. Up to the current point, the system includes the following possibilities: 
- preparation of hydrophilic microparticles of different polymers 
- no use of toxic substances is necessary 
- suitable cleaning and drying process for hydrophilic microparticles 
- particle stability at room temperature under air conditions for at least 11 months, depending 
on the formulation 
- encapsulation of hydrophilic compounds into hydrophobic nanoparticles 
- encapsulation of hydrophobic nanoparticles into hydrophilic microparticles 
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- encapsulation of hydrophilic compounds into hydrophilic microparticles 
- surface modification of hydrophobic nanoparticles for targeting 
- preparation of porous dextran microparticles 
 
All used substances are not classified as ‘toxic’; however, at certain concentrations they are toxic to 
the human body. The lungs are a very sensitive organ and might react to some of these substances, 
even at low concentrations. Currently, there are no polymers approved for pulmonary drug delivery 
by EMA or FDA, but it is likely that especially biopolymers such as dextran do not show a severe impact 
on the lungs, if used. The organic solvents and stabilizers are more problematic. For a final formulation, 
they have to be minimized. For pentane, this should not be much of a problem, as it is very volatile 
and will not mix with the hydrophilic particles. Ethyl acetate also would not mix with the particles and 
should be possibly removed by freeze drying. Also, ethyl acetate is contained in, for example, wine, 
fruits and some kinds of nail polish. An ingestion and inhalation of smaller amounts is obviously without 
risk for a healthy person. Acetonitrile is more toxic than ethyl acetate, but not essential for the drying 
process. It has been used in this thesis, because its freezing point is at -45 °C, and it was therefore 
suitable for freeze drying from an organic solvent on a laboratory scale. For an industrial application, 
an exchange to ethanol and subsequent freeze drying would be more suitable and less toxic.  
The stabilizers, on the other hand, could be a major problem for pulmonary application, as they cannot 
be removed by freeze drying. Since they are very hydrophobic, it is not clear whether they dissolve in 
the alveolar lining fluid or not, but if they do, they have the potential to change its properties and affect 
the breathing ability. 
 
Some features of the system are only assumed and could not be proven within this thesis: 
- particle sizes prepared with multiple membrane cycles are suitable for lung deposition 
- particle sizes prepared with multiple membrane cycles are suitable for entering hair follicles 
These features require future work to prove or disprove them. 
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5 Outlook 
While the aimed goal, systemic delivery to the lungs, has not been reached yet, the given results are a 
good basis for making it possible in future work. The prepared particles’ sizes were all in range for 
getting to the deep lung; however, flight studies with, for example, a cascade impactor or a next 
generation impactor (NGI) would be necessary to see how much of a prepared powder could actually 
be deposited. This is especially important considering the hollow nature of some particles and the 
resulting change in aerodynamic behaviour. 
The use of Pluronic F-127 as porosity agent and its practicability in the preparation process would have 
to be examined in more detail. Up to now, it is just an interesting additional feature of the method of 
preparation and not part of its core properties. For washing out Pluronic F-127, acetonitrile is 
necessary, whereas it was only used as a substitute for the purpose of freeze drying because of its low 
freezing point, and could be exchanged easily by other organic solvents for non-laboratory scale 
applications. Also fully enclosed Pluronic F-127 would not be removed by washing and would then be 
delivered to the lungs, where it could be problematic for the alveolar lining fluid. 
Furthermore, the parameters of toxicity need to be addressed in future experiments. The exact 
amounts of remaining stabilizers and solvents in the particles are still unknown but necessary for any 
final application.  
Lastly, all hydrophilic polymers used in this thesis are not officially approved for pulmonary application. 
For any commercial product in the future, this step has to be taken as well. If no polymers are desired, 
salts or non-polymeric sugars might work as well to prepare particles. 
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6 Zusammenfassung 
Die Dissertation besteht aus drei Elementen: der Einkapselung des Peptidwirkstoffs Desmopressin 
acetat in PLGA Nanopartikel (3.1), die Entwicklung einer Methode zur Herstellung von Mikropartikeln 
aus hydrophilen Polymeren (3.2) und der Einkapselung der PLGA Nanopartikel in eben diese 
hydrophilen Mikropartikel (3.3). 
Die PLGA Nanopartikel werden mit einer leicht modifizierten „Double Emulsion Solvent Diffusion“-
Methode hergestellt. Die zentrale Änderung zu gängigen Ansätzen ist, dass vor der Emulgierung mit 
einer Ultraschall Sonde keine Durchmischung der beiden Phasen vorgenommen wurde und das 
organische Lösungsmittel nach der Herstellung durch Abzentrifugation der Partikel und Verwerfen des 
Überstands und nicht durch Verdampfen entfernt wurde (2.2.2). Die derart hergestellten Nanopartikel 
waren im Größenbereich zwischen 106 und 131 nm (hydrodynamischer Durchmesser) mit PDI < 0,1. 
Zetapotential und pH-Werte wurden ermittelt zwischen -38 und -44 mV und pH 5,5 und 5,9 (3.1.1). Die 
Beladung der Partikel wurde durch eine Doppelemulsion im ersten Schritt realisiert. Hierbei wurden 
unterschiedliche Stabilisatoren in der Primäremulsion getestet, um feststellen zu können, ob diese 
einen Einfluss auf die Einkapselung haben. Verglichen wurden alle Ergebnisse statistisch mit einer 
Kontrolle, in der lediglich die Oberfläche beschichtet war (keine Doppelemulsion). Es konnte hierbei 
gezeigt werden, dass es einen signifikanten Unterschied zwischen der Einkapselung unter 
Zuhilfenahme des Stabilisators Pluronic F-68 und dem Beschichtungsansatz gab. Des Weiteren war 
auch der Unterschied zwischen Pluronic F-68 und einer Kontrolle ohne Stabilisatoren (Doppelemulsion, 
aber Einkapselung ohne Stabilisator) signifikant unterschiedlich. Die beiden Kontrollen jedoch zeigten 
untereinander keinen signifikanten Unterschied in der Beladung, was den Schluss zulässt, dass für eine 
Einkapselung in die Partikel ein Stabilisator nötig ist. Die Beladungseffizienz war im besten Experiment 
(Pluronic F-68) hoch genug, um mit kommerziell erhältlichen Formulierungen mitzuhalten, die 
Einkapselungseffizienz allerdings war mit 6 bis 9% zu niedrig für eine sinnvolle Anwendung (3.1.3). 
Neben der quantitativen Analyse des Peptids mittels HPLC wurde auch mittels LC-MS geprüft, ob das 
Peptid durch die Einkapselung Schäden davonträgt, was verneint werden konnte (3.1.4). In einem 
weiteren Experiment wurden die PLGA Nanopartikel mit hLF-Peptid, einem Penetrationsverstärker, 
durch Inkubation beschichtet. Nach der Inkubation konnte gezeigt werden, dass das Peptid für 
mindestens 7 Tage stabil in wässriger Dispersion auf den Partikeln verbleibt. Neben der Beladung war 
auch eine Funktionalisierung der Partikel möglich (3.1.5). 
Im zweiten Teil wurde ein Transportsystem, primär für pulmonale Applikation entwickelt. Hierbei 
wurde besonderer Wert darauf gelegt, das System so flexibel wie möglich zu halten, um es über diese 
Dissertation hinaus auch für andere Anwendungen einsetzen zu können. Das erarbeitete System ist 
eine Abwandlung der „Emulsion Diffusion“-Methoden, anhand derer auch die PLGA Nanopartikel 
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hergestellt wurden. Da sich die Phasen der Emulsion, die für die PLGA Nanopartikel eingesetzt wurden, 
aber nicht einfach vertauschen ließen, musste ein Zwischenschritt eingefügt werden, in dem die 
Emulsion in einem anderen Lösungsmittel als dem Präzipitationsmittel hergestellt wird (3.2). Das 
daraus entstehende Dreiphasensystem ist in der Lage, Partikel aus unterschiedlichen hydrophilen 
Polymeren (z.B.: Dextran, Chitosan, Alginat, Gelatine, Glucomannan und Lignin) herzustellen (3.2.3). 
Die Größen der Partikel, die mit dieser Methode hergestellt werden, lassen sich über die Größe der 
Emulsionstropfen steuern. Um möglichst homogene Emulsionen herzustellen, wurde eine 
Membranemulgierung eingesetzt, bei der die zu dispergierende Phase mehrfach eine Membran 
passierte und damit entsprechend der Porengröße der Membran in kleine Tropfen dispergiert wurde. 
Hierbei konnten Partikel aus Chitosan im Größenbereich um 500-600 nm hergestellt werden (3.2.1). 
Zur Vereinfachung und um schneller arbeiten zu können, wurde für einige Experimente die Emulsion 
mit einem Hochdruckhomogenisator hergestellt, oder es wurde bei der Membranemulgierung auf 
multiple Membranpassagen verzichtet. Neben der Herstellung wurde auch eine Trocknungsmethode 
entwickelt. Hierfür wurden die Partikel zunächst mit organischem Lösungsmittel von überschüssigem 
Stabilisator befreit und dann mit flüssigem Stickstoff in organischem Lösungsmittel eingefroren und 
daraus gefriergetrocknet (2.2.3). Derart getrocknete Partikel wiesen eine Lagerstabilität (in mit Luft 
gefüllten abgeschlossenen Gefäßen) von mindestens 11 Monaten auf. Einzig die Dextran Partikel 
wiesen nach 11 Monaten eine glattere Oberfläche auf, was auf ein Anlösen der Oberfläche in der 
Luftfeuchtigkeit hindeutet (3.2.3). Auch die direkte Einkapselung von Desmopressin in Dextranpartikel 
mittels dieser Methoden wurde getestet und führte zu deutlich höheren Einkapselungseffizienzen als 
bei PLGA Nanopartikeln (3.2.4). In einem weiteren Experiment wurde die Dextranlösung vor der 
Emulgierung mit Pluronic F-127 gemischt. Diese Mischung führte zu einer Phasentrennung zweier 
wässriger Phasen. Dieser Effekt konnte genutzt werden, um poröse Partikel herzustellen, indem beide 
Phasen vor der Emulgierung gut durchmischt wurden und dann gemeinsam emulgiert und präzipitiert 
wurden. Die daraus entstehenden Partikel bestanden aus zwei festen Phasen, von denen eine durch 
ein organisches Lösungsmittel ausgewaschen werden konnte. Die resultierenden Partikel hatten 
Löcher und waren porös (3.2.2). 
Im dritten Teil wurden dann erneut PLGA Nanopartikel hergestellt aus einem Fluoresceinamin-
gelabelten PLGA. Diese Nanopartikel wurden in Dextranpartikel eingekapselt und mittels 
Konfokalmikroskopie untersucht. Auf diese Weise konnte gezeigt werden, dass sich PLGA Nanopartikel 
in Dextranpartikel einkapseln lassen (3.3). 
Ein flexibles hydrophiles Trägersystem zum Transport beladener und funktionalisierter hydrophober 
Nanopartikel konnte erfolgreich hergestellt werden. 
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